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Abstract 
Gaucher disease, the most common lysosomal storage disorder, is caused by mutations in the 
GBA gene which codes for the enzyme glucocerebrosidase (GCase) resulting in its deficiency.  GCase 
deficiency results in the accumulation of its substrate glucosylceramide (GlcCer) within the lysosomes 
leading to various severities of hepatosplenomegaly, bone disease and neurodegeneration.  For most 
forms of Gaucher disease, the mutations in the GBA gene cause the enzyme to misfold but retain 
catalytic activity.  However, the misfolded mutant enzyme is recognized and degraded by the 
endoplasmic reticulum-associated degradation (ERAD) pathway prior to delivery into the lysosome.  
Symptoms begin to show in patients when the function of the defective enzyme drops below 10-20% 
residual enzyme activity.  
There are currently three therapeutic approaches to treat Gaucher disease: enzyme 
replacement therapy (ERT), substrate reduction therapy (SRT), and a relatively recent addition, enzyme 
enhancement therapy (EET) through the use of pharmacological chaperones.  Many pharmacological 
chaperones are competitive inhibitors that are capable of enhancing lysosomal GCase activity by 
stabilizing the folded conformation of GCase enabling it to bypass the ERAD pathway.  Once the mutant 
enzyme enters the lysosome, high levels of GlcCer can outcompete the competitive inhibitor binding to 
the enzyme, thus partially restoring the hydrolytic pathway.   
For this thesis, a series of alkylated aminocyclitol derivatives have been synthesized and 
evaluated as competitive inhibitors of GCase with the intent of discovering specific and efficient 
pharmacological chaperones for Gaucher disease.  Importantly, we have discovered that N,O-alklyated 
inosamines are potent inhibitors of GCase and therefore are lead compounds as a potential new EET for 
the treatment of Gaucher Disease. 
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Based on the potency of the alkylated inosamines as reversible inhibitors, we designed and 
synthesized several alkylated conduritol aziridine inhibitors to be used as mechanism-based inactivators 
of GCase.  All three aziridine compounds synthesized were potent inhibitors of GCase with ki/Ki values 
ranging from 3.837 to 3674 mM-1min-1.  For comparison purposes, our most potent inhibitor is 37 times 
more effective than the best published inhibitor of GCase.  In addition, the alkylated aziridines were 
shown to be cell permeable and effective at inhibiting GCase inside of living HeLa cervical cancer cells, 
thus demonstrating their enormous potential as activity based probes, GCase labeling agents or 
potential molecular imaging agents for assessing ERT. 
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Chapter 1: General Introduction 
1.1  Glycosidases  
Glycosidases (glycoside hydrolases) carry out the hydrolytic cleavage of the carbon – oxygen 
acetal or glycosidic bond.  The glycosidic bond is formed between the carbon of the glycone and oxygen 
of the aglycone and is cleaved by the enzyme in the presence of water (Figure 1.1).  
 
Figure 1.1:  A general glycosidase-catalyzed hydrolysis reaction of a glucoside. 
Glycosidases have been classified in a variety of ways based on the following properties: 
1) Cleavage site. Glycosidases that hydrolyze the glycosidic bond within an oligosaccharide chain 
are called endo-glycosidases, while those that hydrolyze the residues at terminal ends are called 
exo-glycosidases.  
2) Anomeric specificity to the substrate.  Glycosidases typically catalyze the hydrolysis of either α- 
or β- glycosidic linkages and will be unable to, or have minimal capability to, hydrolyze the 
alternate anomer.  
3) Mechanism of hydrolysis.  Glycosidase release the product glycone having a specific α- or β-
stereochemistry at the anomeric carbon through the use of either an inverting or retaining 
mechanism when hydrolyzing the glycosidic linkage.   
4) Reaction catalyzed.   Many enzymes have been categorized by the Nomenclature Committee of 
the International Union of Biochemistry and Molecular Biology (NC-IUBMB) based on the 
reaction they catalyze and can be found on the peer reviewed1 website http://www.enzyme-
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database.org.  Hydrolases are class 3 enzymes given an Enzyme Commission number of EC 3 
followed by a number indicating the bond hydrolyzed, the catalytic mechanism, and a further 
subclass linked to the specific enzyme. For example, β-D-glucocerebrosidase is EC 3.2.1.45, 
where the 3 indicates the enzyme is a hydrolase, 3.2 specifies a glycosidase, 3.2.1 indicates an 
O-glycosidase, and finally 3.2.1.45 indicating specifically β-D-glucocerebrosidase.  
5) Amino acid sequence.  Glycosidases have been classified based on their amino acid sequence 
and folding similarities into a large peer reviewed2 Carbohydrate-Active enZYmes (CAZY) 
database that can be found at http://www.cazy.org.   Glycosidases with similar sequences are 
grouped into one of 132 families, and the families are grouped into 14 different clans based on 
the folded protein structure.  
Glycosidases are important enzymes because of their ability to enhance the reaction rates for 
the selective hydrolysis of a variety of saccharides necessary for vital cell functions such as energy 
storage and production, cell wall composition, and signalling molecules.3  Glycosidases are known to be 
one of the most efficient enzymes capable of the hydrolysis of molecules like cellulose, with an effective 
1017(kcat/knon) rate enhancement.
4  To put this into perspective, the half-life for the spontaneous 
hydrolysis of cellulose is 4.7 million years,4a while the glycosidase-catalyzed half-life can be as low as 
0.693ms.4b  
1.1.1 Glycosidase Mechanisms 
Glycosides can exist in two possible diastereomeric configurations depending on the orientation 
of the bond at the anomeric carbon. Drawn in Haworth projections, if the group attached to the 
anomeric carbon is on the same side of the ring as the carbon atom that determines the configuration 
(D- or L-), then it is the β-anomer, and if they are on opposite sides, then it is the α-anomer. 
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Glycosidases catalyze the hydrolysis of a specific glycosidic linkage using a mechanism that results in the 
retention or inversion of the stereochemistry at the anomeric center (Figure 1.1.1).  
 
Figure 1.1.1: Stereochemical result of inverting and retaining glycosidase catalyzed reactions 
There are many different glycosidases that use a variety of mechanisms to catalyze their 
hydrolytic reactions including substrate assisted catalysis, proton transferring networks, non-carboxylate 
residues, and exogenous bases and nucleophiles.5  However, for the purpose of this thesis, we will 
discuss only the most common and thoroughly studied carboxylic glycosidases that rely on carboxylic 
acid functional groups for catalysis. 
1.1.1.1 Inverting glycosidases 
 During hydrolysis, an inverting glycosidase catalyzes the inversion of the anomeric carbon in the 
reactant to the alternate anomer in the product.  For example, a β-inverting glucosidase will hydrolyze a 
β-glucoside producing α-glucose as the glycone product.  These glycosidases rely on a pair of carboxylic 
acid functional groups (Glu or Asp) located on average 10.5 Å apart which allows for simultaneous 
binding of both the substrate and water in the active site.3, 4b  In the unbound state, one of the 
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carboxylic acid residues within the active site is deprotonated acting as a general base while the other 
remains protonated and acts as a general acid.  The reaction occurs through a single displacement 
mechanism where the general base removes a proton from water to enhance its nucleophilicity, 
promoting the oxygen to attack the anomeric carbon of the substrate, while the general acid protonates 
the leaving aglycone oxygen allowing the products to dissociate.5  The reaction results in the formation 
of an oxocarbenium ion-like transition state which is stabilized through flattening of the sugar into a 
half-chair or B boat conformation to favor hydrogen bonding between the substrate and nucleophile 
and through electrostatic interactions.4b  The mechanism of a general inverting β-glucosidase is shown in 
Scheme 1.1.1.1. 
 
Scheme 1.1.1.1: Accepted mechanism of inverting β-glucosidase 
1.1.1.2 Retaining glycosidases 
 The majority of retaining glycosidases use a double displacement mechanism involving two 
inversion steps that result in the net retention of the anomeric configuration in the reactant and 
product.  Proposed by Koshland in 1953,6 the first step in catalysis involves glycosylation of the enzyme 
forming a covalent glycosyl-enzyme intermediate followed by a deglycosylation step. Retaining 
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glycosidases utilize a pair of carboxylic acid functional groups (Glu or Asp) that are 5.5 Å apart, spaced 
much closer together than the carboxylic acid functional groups found 10 Å apart in inverting 
glycosidases. Having the pair of carboxylic acid functional groups 5.5 Å apart prevents simultaneous 
binding of water and substrate in the enzyme’s active site, thus preventing direct hydrolysis of the 
substrate and permitting the two step double displacement reaction.3, 4b  In the first step of catalysis, 
one of the carboxylic acids, in the basic form, acts as a catalytic nucleophile attacking the anomeric 
carbon and displacing the aglycone group from the sugar ring.  The second carboxylic acid 
simultaneously protonates the leaving oxygen thus promoting formation of the covalent glycosyl-
enzyme intermediate and the liberated aglycone product.4b  The second step of the mechanism occurs 
through hydrolysis of the glycosyl-enzyme intermediate assisted by the carboxylate residue acting as a 
general base.  This step produces free enzyme and the glycone having the retained stereochemistry at 
the anomeric carbon.4b  In both catalytic steps there is an oxocarbenium ion-like transition state formed 
and stabilized through hydrogen bonding and electrostatic interaction with various active site residues.4b  
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The mechanism of a general retaining glycosidase is shown in Scheme 1.1.1.2.   
 
Scheme 1.1.1.2: Accepted mechanism of retaining β-glucosidase 
In 1967 an alternate mechanism was proposed by Phillips7 which involved formation of an ion-
pair intermediate where the carbonium ion would be shared with the ring oxygen causing the ring to 
take up the half-chain conformation.  This translates to an oxocarbenium-ion transition state in the half-
chair conformation.   The formation of a covalent intermediate in the mechanism of retaining 
glycosidases was later confirmed through the use of α-deuterium isotope effects and active site 
irreverisible inhibition.  Studies involving α-deuterium isotope effects showed the hydrolysis of glucosyl-
enzyme intermediates (deglycosylation step) gave kH/kD = 1.2-1.25.
8  A kH/kD >1 indicates a decreasing 
coordination number from the intermediate to the transition state.  In the retaining glycosidase 
mechanism, a kH/kD >1 is only possible when the substrate is covalently attached because the anomeric 
carbon changes from sp3 to sp2 going from the transition state to the product.  If there was an ion-pair 
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intermediate as theorized by Phillips, then coordination would increase from sp2 to sp3 and a kH/kD <1 
would result.  Further evidence of a covalent intermediate in the double displacement mechanism 
comes from X-ray crystallography and mass spectroscopy studies with active site irreversible inhibitors 
such as 2-deoxy-2-fluro-D-glycosyl fluorides9 revealing the formation of a covalent inhibitor-enzyme 
intermediate.  The inclusion of the electronegative fluorine at the C2 position of glucose destabilizes the 
oxocarbenium ion-like transition states resulting in trapping and observation of the covalent 
intermediate.10   
1.1.2 Glycosidase Inhibitors 
Glycosidases are involved in a wide variety of pathways within the cell so inhibiting activity of 
specific glycosidases can reveal information about what pathways are modified in disease states and 
how glycosidases can be regulated to restore normal function.  Glycosidase inhibitors have shown 
therapeutic potential for the treatment of viral infection, diabetes, obesity, cancer, and genetic 
disorders.11  Viral infections such as influenza, hepatitis and HIV may be treated by disrupting cell-virus 
recognition through inhibiting the activation of signalling oligosaccharides on the cell surface.11b  
Diabetes and obesity can be treated by inhibiting intestinal glycosidases to lower blood glucose levels11b 
or inhibiting hepatic glucose production.12  Elevated levels of glycosidases in the cells and tumor 
microenvironment are seen in malignant cancers and could be inhibited to prevent metastasis.13  Clinical 
trials are currently ongoing for genetic disorders such as lysosomal storage diseases where there are 
deficiencies in glycosidases that may be treated with competitive glycosidase inhibitors acting as 
pharmacological chaperones.12, 14  In addition, glycosidase inhibitors are very important tools for medical 
and biotechnological studies due to their ability to modify cellular functions.   
 Glycosidase inhibitors can be classified by their interaction with the enzyme as covalent or non-
covalent inhibitors.  Covalent inhibitors will form an irreversible covalent bond with the enzyme, usually 
8 
 
to one of the residues in the active site which inactivates the enzyme.  Covalent inhibitors can bind to a 
non-active site pocket on the enzyme but need to induce a conformational change of the active site to 
inactivate the enzyme.  Non-covalent inhibitors bind reversibly to the enzyme acting as competitive, 
non-competitive and uncompetitive inhibitors.  
1.2 Lysosomal Storage Diseases 
 Lysosomal storage diseases (LSDs) are a group of genetic disorders in which there is a deficiency 
in the proteins involved in the lysosomal catabolic pathways.  Lysosomes are organelles within cells that 
break down and recycle cellular waste materials through the action of over 50 hydrolytic enzymes from 
various enzyme classes.  Deficiency in the lysosomal proteins results in accumulation of partially 
processed substrates within the lysosome leading to complex and variable disease symptoms.  Some of 
the most well studied LSDs include Tay Sachs, Fabry, Pompe and Gaucher diseases.14a, 14c, 15  Of the 
known LSDs, all are caused by autosomal recessive genes, except for the X-linked recessive genes 
involved in Hunter’s syndrome and Fabry’s disease, and most involve nervous system function.16  There 
are 46 LSDs that can be classified into six categories based on their functional defect:16 
1) Lysosomal hydrolase.  The gene encoding one of the 50 lysosomal hydrolases is mutated 
resulting in the expression of a crippled enzyme that is structurally unstable or unable to 
properly catalyze substrate degradation within the lysosome.   
2) Post-translational processing.  Multiple sulfatase deficiency (MSD) is the only LSD in this 
category.  Post-translational modification of a cysteine residue into an aldehyde is required for 
all sulfatases to function but modification of the cysteine residue in the enzyme does not occur 
in MSD resulting in the excess storage of sulfate containing lipids in the lysosome.  
3) Trafficking of lysosomal enzymes.  This category includes multiple types of Mucolipidosis LSDs. 
N-acetylglucosamine-1-phosphate transferase, one of the many enzymes responsible for 
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attaching signalling molecules to lysosomal enzymes, is defective so the lysosomal enzymes are 
not recognized for transported into the lysosome.  
4) Lysomal enzyme protection.  Galactosialidosis is the only LSD in this category.  Its mechanism is 
poorly understood but a mutation of the protective protein, Cathepsin A, prevents the 
formation of a stabilizing complex with β-galactosidase and α-neuramidase resulting in their 
deficiencies. 
5) Soluble non-enzymatic proteins.  LSDs in this category result from deficiencies in various soluble 
proteins such as the lipid transfer proteins in GM2 gangliosidosis activator protein deficiency.  
These proteins interact with other proteins to form complexes, modify activity, or activate 
transcription.  
6) Transmembrane non-enzyme proteins.  Transport proteins responsible for the selective 
transport of materials across the cell and lysosomal membranes are deficient.  For example, 
Nieman-Pick C can be caused by a defective cholesterol transporter or defective lysosomal-
cholesterol binding protein. 
Of the 46 lysosomal disorders, 29 of them are due to defects in a lysosomal hydrolase.  Many of these 
hydrolases are part of long catabolic pathways that become interrupted resulting in the excessive 
storage of partially processed substrates.  The catabolic pathway of gangliosides within the lysosomes 
can be seen in Scheme 1.2.1. 
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Scheme 1.2.1: The enzymatic degradation of gangliosides in the lysosome.  Enzymes are shown in black 
and the diseases resulting from their deficiency are shown in red. Adapted from Butters et al.17 
Within the lysosomal hydrolase class of LSD’s, the specific mutation affects the nature and 
severity of the disease symptoms.  However, even with commonly found mutations, the pathology and 
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progression cannot be reliably predicted due to the many downstream pathways affected by substrate 
accumulation.18  This is exemplified by patients with the same genotype and genetic background 
displaying a range of different phenotypes for a given LSD.18  Most LSDs display infantile, juvenile and 
adult forms named for the stage of life most complications can be detected and diagnosed.  The infantile 
forms are the most severe with virtually no residual enzyme activity resulting in early death due to 
neurological involvement while the juvenile and adult forms have low to moderate residual activity, 
slowly develop and are less severe.18-19   
The specific mutations found in the gene encoding the hydrolase that causes the LSDs can 
dramatically affect both protein stability and catalytic activity.  Enzymes are synthesized by ribosomes in 
the endoplasmic reticulum (ER) in an unfolded state.  The protein then begins to form a proper 3-
dimensional structure, typically  with the aid of various helper molecules that promote the formation of 
the folded conformation.19  Proteins that do not fold properly can aggregate and lead to cell toxicity.  
Therefore, misfolded proteins are recognized by a quality control mechanism that labels unfolded 
proteins with ubiquitin directing them into the endoplasmic reticulum associated degradation (ERAD) 
pathway.19  The consistent destruction of the misfolded lysosomal enzyme in the ERAD pathway 
ultimately leads to insufficient levels of enzyme reaching the lysosome.  Critically, experiments have 
shown that only 10-20% residual enzyme activity is sufficient to prevent substrate accumulation in both 
Gaucher and Tay-Sachs diseases.17   
Since most mutations in the amino acid sequence lead to the expression of an enzyme that 
maintains catalytic activity, various therapeutic strategies have been developed to improve delivery of 
the functional enzyme to the lysosomes including enzyme replacement therapy (ERT) and enzyme 
enhancement therapies (EET) by using pharmacological chaperones.  Alternatively, substrate reduction 
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therapy (SRT) blocks the metabolic pathways that generate the substrates in order to decrease the rate 
of substrate accumulation within the lysosomes.  
1.2.1 Enzyme Replacement Therapy 
Enzyme replacement therapy attempts to supplement the residual enzyme activity of the 
defective enzyme by exogenous administration of a recombinant and modified enzyme.  Recombinant 
enzymes must be modified to display glycan chains on the surface of the protein that target endocytotic 
receptors found on specific cell types affected by the specific LSDs.14a  Different cell targets require 
distinct oligosaccharides including important terminal residues such as mannose, mannose-6-phosphate, 
and asialoglycoprotein that target the mannose receptor, mannose-6-phosphate receptor and 
asialglycoprotein receptor respectively.14a  Once bound to the receptor, the receptor-enzyme complex is 
internalized into the cell through endocytosis thus delivering functional enzyme to the lysosomes of the 
diseased cells.  Despite having enormous success with the treatment of several LSDs such as Gaucher, 
Fabry, Pompe, MPS I, MPS II, and MPS VI diseases14c, there are several limitations with ERT such as the 
inability to reduce secondary symptoms from substrate storage such as inflammation and apoptosis, the 
inability to penetrate the blood-brain barrier to treat neurological symptoms, the potential to develop 
an immune response to the recombinant enzyme and the expensive costs of therapy ($90,000-$720,000 
annually per patient14c).14a   
1.2.2 Substrate Reduction Therapy 
 Substrate reduction therapy is often used concurrently with ERT to treat LSDs. ERT functions to 
remove accumulated substrate by delivering enzyme to the lysosomes while SRT prevents substrate 
accumulation by blocking the upstream metabolic pathways that produce the substrate as a normal part 
of metabolism.  SRT requires the administration of inhibitor molecules that will partially inhibit enzymes 
involved in the synthesis of the target substrate.17  Currently, SRT has been applied to the inhibition of 
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enzymes involved in glycosphingolipid synthesis and has shown potential to improve symptoms of LSDs 
caused by deficiencies in the glycosphingolipid catabolic pathway.14a, 17   Gaucher disease, which is 
caused by a defect in the lysosomal β-glucosidase glucocerbrosidase (GCase), is the first disease used for 
evaluating SRTs.  There are now a number of inhibitors targeting ceramide-specific glucosyltransferase 
used in clinical trials such as N-butyl-deoxynojirimycin.17  There can be wide ranging problems with SRT 
for the treatment of LSDs because the metabolic pathways inhibited normally perform vital functions for 
the cells. The side effects can become especially significant when applying the treatment to young 
children during development.18  However, these small molecule inhibitors are capable of passing the 
blood-brain barrier and can therefore improve the outcome of patients with neurological involvement 
which are expressed in the severe LSD cases at young ages.  Currently the only clinically approved and 
commercially available compound for SRT is Zavesca (N-butyl-deoxynojirimycin) for the treatment of 
Gaucher and Niemann-Pick diseases but many compounds are currently in clinical trials.20 
1.2.3 Enzyme Enhancement Therapy 
 Enzyme enhancement therapy (EET) involves the use of pharmacological chaperones that are 
able to enhance the residual enzyme activity by stabilizing the properly folded mutant enzymes and 
preventing degradation by ERAD.  As mentioned above, many LSDs result from a genetic mutation that 
results in the expression of a catalytically active mutant protein that is degraded prior to trafficking into 
the lysosome.  In order to bypass the ERAD quality control mechanism, a defective enzyme would need 
to enter a properly folded state long enough to be transported out of the ER and trafficked into the 
lysosome.  A potential solution is to use a competitive inhibitor that binds to the active site of the 
enzyme stabilizing the folded conformation.  Once the catalytically active mutant enzyme enters the 
lysosome, excessively stored substrate outcompetes the inhibitor and partial restoration of the pathway 
can result.   Although the idea of using competitive inhibitors to increase enzymatic activity is 
counterintuitive, experiments have clearly demonstrated that this strategy is effective at increasing 
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lysosomal hydrolase activity.19  In fact, EET as a new therapy for Gaucher disease has already been 
shown to be an effective treatment for individuals who have mutations that retain enzymatic activity.21  
Individuals with mutations that abolish catalytic activity do not show any improvement with EET 
chaperones21 clearly indicating that the improvements observed with EETs are due to increased enzyme 
transport and reduced ERAD.  The three therapeutic strategies for the treatment of Gaucher disease are 
summarized in Scheme 1.2.1 below.  
 
Scheme 1.2.2: The three therapeutic strategies, SRT, ERT and EET, employed to reduce GlcCer storage in 
the treatment of Gaucher disease.   
15 
 
1.2.4 Gaucher Disease 
 Phillip Gaucher first identified a patient with Gaucher disease in 1882 based on the enlarged 
spleen of a 34 year old woman.22  Gaucher disease is the most common lysosomal storage disorder 
occurring with a frequency of one in 40,000-50,000 live births23 compared to the one in 7,70024 
occurrence of all lysosomal storage disorders combined.  Certain ethnic groups can have variable 
prevalence of these diseases like the Ashkenazi Jews who have a one in 800 frequency of Gaucher 
disease.21  Gaucher disease results from more than 300 known mutations in the GBA gene coding for β-
glucocerebrosidase (GCase).22  The resulting mutant enzyme is degraded through ERAD resulting in the 
accumulation of the substrate glucosylceramide (GlcCer) within the lysosomes leading to the disease 
state.  The severity of the disease depends not only on the residual enzyme activity in the lysosomes, 
but also the extent of macrophage involvement.  Macrophages may be activated either by the excess 
storage of GlcCer due to sphingolipid’s ability to trigger inflammation and apoptosis, or activated by 
cellular pathways detecting the abnormal folding of protein within the ER which can also initiate 
inflammation and apoptosis.23  There is some evidence supporting the influence of protein misfolding 
being the primary cause of the disease symptoms when there is CNS involvement due to extensive 
neuronal death without requiring accumulation of GlcCer.23  
Patients with Gaucher disease are diagnosed at an average age of 9.5 years24  and can present as 
one of three different pathologies.  The most prevalent form of Gaucher disease is Type 1 which is a 
non-neuropathic form affecting 90% of Gaucher patients.14a  This form characterized by the presence of 
hepatosplenomegaly and bone disease with frequent occurrence of haematological disorders and 
growth retardation.23  Type 2 Gaucher disease is the most severe form of the disease with a median age 
at death of 9 months.23  The disease symptoms can be expressed within the first few days of life and 
present with hepatosplenomegaly and severe neurodegeneration.  Type 3 Gaucher disease is an 
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intermediate form of the disease and can present with variable severities of hepatosplenomegaly, bone 
disease and neurodegeneration.23 
1.2.5 Glucocerebrosidase 
 GCase (EC 3.2.1.45) is a retaining β-glucosidase enzyme of glycosidase hydrolase family 302 
responsible for the cleavage of β-glucosylceramide into the glycone, β-D-glucose, which is readily used 
by the cell, and the aglycone, ceramide, which is further catabolised into sphingosine and fatty acids by 
other enzymes in the glycosphingolipid degradation pathway (Scheme 1.2.1). 25  
 
Scheme 1.2.3: Glucocerebrosidase catalyzed hydrolysis of glucosylceramide 
Since GCase is a retaining β-glucosidase, it utilizes the double displacement mechanism (Scheme 
1.1.1.2) with Glu340 as the catalytic nucleophile and Glu235 as the general acid/base.26  In order to access 
the GlcCer within the lysosome, GCase requires Saposin C which is hypothesized to act as a GlcCer 
“solubilizer” or as “liftase” proteins.27  In the solubilizer model, saposin C would extract GlcCer from the 
phospholipid bilayer forming a soluble lipid-protein complex and allow interaction with the aqueous 
soluble GCase.27  In the liftase model, both saposin C and GCase would bind to the lipid bilayer with 
saposin C functioning to facilitate access to GlcCer within the membrane.27   In addition to saposin C, 
negatively charged lipids such as 1,2-diacyl-sn-3-phosphoinositol and bis(monoacylglycero)phosphate as 
well as low pH are required for full GCase activity.27   
While the primary location of GlcCer catabolism is within the lysosome, a second integral 
membrane GCase capable of GlcCer hydrolysis has been identified.25  This non-lysosomal GCase 
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(NLGCase) exhibits no homology with GCase and has different substrate and inhibitor specificities.25  
NLGCase is encoded on a unique GBA2 gene allowing it to remain functional in patients with Gaucher 
disease mutations.25  NLGCase catabolism of GlcCer generates ceramide that is rapidly converted into 
sphingomyelin by transfer of phosphorylcholine to ceramide from phosphatidylcholine (PC).25  In 
patients with Gaucher disease, it has been shown that PC synthesis has been increased25 indicating an 
up-regulation in the conversion of ceramide to sphingomyelin and therefore increase in GlcCer 
catabolism by NLGCase.  The presence of this second GCase may explain why only certain organs 
containing cells with abundant lysosomes like macrophages are primarily affected while others remain 
normal in Gaucher patients.   
Broad specificity cytosolic β-glucosidase (CBA), is a third enzyme present in cells that is capable 
of GlcCer hydrolysis.28  As the name suggests, CBA is capable of hydrolyzing a wide variety of both 
natural and artificial β-D-glucoside, β-D-galactoside, β-D-fucoside, β-D-xyloside, and α-L-aribinoside 
compounds.29  CBA is encoded on the GBA3 gene and is thought to be responsible for some of the 
variability seen in Gaucher disease, but there is also strong evidence contradicting this idea.28-29, 29c 
Cerezyme™ (imiglucerase), the second generation recombinant GCase used for the treatment of 
Gaucher disease, is produced by genetically engineered Chinese hamster ovary cells (CHOC) and differs 
from the human GCase at position 495 where an arginine residue has been replaced by a histidine.  The 
enzymes generated by the CHOC have complex oligosaccharide chains at three of the four glycosylation 
sites on the enzyme and are expressed as a glycoprotein terminating with sialyl or galactosyl groups.30  
In order for Cerezyme to be properly recognized by the mannose receptors on macrophages, the 
primary cell type involved in Gaucher disease, the glycan chains must terminate with mannose residues.  
To produce terminal mannose residues on the glycan chains, the enzyme is treated with neuraminidase, 
β-galactosidase, and β-N acetylglucosaminidase.   A third generation enzyme, Velaglucerase, has been 
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recently produced in fibrosarcoma cells and contains highly mannosylated chains that terminate in 
mannose, thus avoiding the costly enzymatic glycan modification steps required for Cerezyme.  Dispute 
over whether Velaglucerase has greater uptake than Cerezyme due to the extent of mannose expression 
on the enzyme surface cannot be proven due to the current inability to track and monitor the extent of 
enzyme uptake within affected cells or diseased organs.  This highlights the need for improved methods 
to monitor the biodistribution of exogenously administered enzyme in order to evaluate new forms of 
the enzyme, improve the efficiency of recombinant enzyme therapeutics and develop the most effective 
treatment options.  
1.3 Research Objectives 
 There are two main aims of this thesis.  The first is the synthesis and enzymatic evaluation of 
novel aminocyclitols as potential chemical chaperones for the treatment of Gaucher disease.  Various 
aminocyclitol derivatives have been synthesized in order to determine the influence of alkyl chain length 
and chain position on affinity towards recombinant GCase.  Various combinations of chain length and 
position can allow for the generation of more specific and efficient pharmacogical chaperones to treat 
the various forms of Gaucher disease.  The second aim is the synthesis and enzymatic evaluation of 
alkylated aziridine derived aminocyclitols that are hypothesized to act as mechanism-based inhibitors of 
glycosidases.  By alkylating the aziridine with a hydrophobic moiety we aim to generate a specific and 
effective inactivator of GCase useful for cell studies, a potential activity based probe for analyzing GCase 
activity in complex mixtures, and a fluorescent or radioactive labelling agent potentially useful for 
tracking the injected enzyme in vivo using non-invasive procedures such as optical or PET imaging.  
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Part A: Aminocyclitol Competitive Inhibitors of Glucocerebrosidase 
1.4 Introduction 
1.4.1 Non-covalent Glycosidase Inhibitors 
 Non-covalent glycosidase inhibitors are among the most studied glycosidase inhibitors.  The 
majority of these compounds have been discovered in nature11a or designed to resemble the transition 
state structure of the hydrolysis reaction.11c  Estimated from the rate enhancement of glycosidases of 
1017(kcat/knon), the dissociation constant of the transition state must be less than 10
-22 M11c indicating the 
theoretical possibility of analogue inhibitors with Ki in the same magnitude.
11b  There are a number of 
different types of natural compounds that mimic the transition state structure such as piperidines, 
pyrrolidines, indolizidines, pyrrolizidines, and nortropanes.11a  Some of the most thoroughly studied 
inhibitors include the iminosugars11-12, 31 and aminocyclitols.31a, 32 Both the iminosugars and 
aminocyclitols are heterocyclic polyhydroxylated compounds containing a nitrogen atom that is 
protonated and positively charged at physiological pH.  Some examples of iminosugars are 
deoxynojirimycin (DNJ), fagomine (FG), and isofagomine (IFG) (Figure 1.4.1).   
 
Figure 1.4.1: Examples of potent non-covalent iminosugar inhibitors  
DNJ was first synthesized in 1968 and was later isolated from Mulberry tree roots and from 
multiple strains of Bacillus and Streptomyces.11a  FG is a naturally occurring compound isolated from the 
seeds of Japanese buckwheat and Moreton Bay chestnut.11a  IFG was rationally designed as a glycosidase 
inhibitor and synthesized in 1994.33  DNJ has comparable Ki values to IFG while IFG generally exhibits a 
greater ability to inhibit the activity of glycosidases than FG.  Both DNJ and IFG are in a chair 
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conformation and are positively charged under physiological conditions but differ in both the positioning 
of the nitrogen atom and the lack of 2-hydroxyl group found in IFG.34  It has been shown that the 
removal of the hydroxyl group in IFG does not substantially influence its affinity to α- and β-
glycosidases.34  Deoxynojirimycin was shown to have Ki values of 47µM, and 25µM while isofagomine 
has Ki values of 0.11µM and 86µM with β-glucosidase (sweet almonds) and α-glucosidase (yeast) 
respectively.34  This suggests that the positively charged nitrogen of the glucosidase inhibitors should be 
at the anomeric position to specifically target β-glucosidases and in the position adjacent to the 
anomeric carbon to target α-glucosidases.  An explanation for the observed differences in binding 
affinity for DNJ and IFG towards α and β glycosidases was hypothesized by Withers4b to involve syn 
interactions between the oxygens of the nucleophilic carboxylate with the anomeric carbon and 2-
hydroxyl group of the substrate in β-glycosidases.  In contrast, there is syn interaction between the 
oxygens of the nucleophilic carboxylate with the anomeric carbon and endocyclic oxygen in α-
glycosidases (Figure 1.4.2 a) and b)).  This theory is supported by the observation that isofagomine, with 
a nitrogen at the anomeric position of the glucose substrate, results in greater inhibition of β-
glucosidases while deoxynojirimycin, with the nitrogen at the adjacent position, has stronger inhibition 
of α-glycosidases (Figure 1.4.2 c) and d)).  These observations demonstrate that inhibitor specificity to 
the desired glycosidase may be tailored by adding a positively charged atom in the position favored by 
the target glycosidase. 
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Figure 1.4.2: Proposed transition states for A) β-glucosidase, B) α-glucosidase. Corresponding inhibitors 
C) Isofagomine, D) deoxynojirimycin. Adapted from Zechel and Withers.4b 
 Aminocyclitols have recently been studied as glycosidase inhibitors because of their antibiotic 
properties.35  It was discovered in the 1970s that saccharide compounds containing a valienamine 
component were capable of inhibiting α-glucosidase activity in the intestines.36  Effort was then put 
forth to develop inhibitors containing the valienamine and valiolamine components as potential 
therapeutic agents for diabetes by limiting monosaccharide uptake in the intestines through inhibition 
of intestinal α-glycosidases (Figure 1.4.3).11c, 36  This later expanded into the development of novel 
aminocyclitols designed to inhibit a variety of different glycosidase targets.  Of particular interest were a 
number of inosamine derivatives that displayed promise as inhibitors of glucocerebrosidase (GCase), the 
β-glucosidase involved in Gaucher disease.32a  These compounds were derivatives of a myo-inositol with 
one of the hydroxyl groups replaced with an alkylated nitrogen showing micromolar Ki values towards 
the recombinant glucocerebrosidase, imiglucerase (Figure 1.4.3).32a  Initial results show that inosamine 
A) B) 
C) D) 
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derivatives can function as potent inhibitors of GCase, but derivatives are needed to understand the 
structure-function relationships in order to optimize Ki values while improving aqueous solubility, 
membrane permeability, glucosidase selectivity and chemical stability. 
 
Figure 1.4.3: Examples of non-covalent inosamine glucosidase inhibitors32a, 36-37 
 
Chapter 2:  Results and Discussion 
2.1 Synthesis 
2.1.1 Synthesis of Substrate 2,4-dinitrophenyl-β-D-glucopyranoside (2,4-DNP-β-D-glc) 
Several colorimetric substrates have been synthesized and used for kinetic studies on GCase. Of 
them, 2,4-dinitrophenyl-β-D-glucopyranoside is the most commonly used because it is readily 
hydrolyzed by β-glucosidases, it releases 2,4-dinitrophenolate that strongly absorbs at 400nm under 
acidic pH enabling continuous assays and is conveniently synthesized.  Because this substrate is not 
commercially available, 2,4-DNP-β-D-Glc was synthesized as shown in Scheme 2.1. 
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Scheme 2.1: Synthesis of the Substrate 2,4-dinitrophenyl-β-D-Glucopyranoside 
 
Reagents and conditions: a) Ac2O, pyr, 0°C-RT, 17Hrs, 95%, b) hydrazine acetate, DMF, 55°C, 2Hrs, 91%, 
c) 2,4-dinitrofluorobenzene, DABCO, DMF, RT, Dark, 51-61%, d) AcCl, MeOH, 4°C, 48Hrs, 37%. 
Compound 3.01 was synthesized by treating D-Glucose with acetic anhydride in pyridine, 
resulting in a mixture of the α- and β- anomer (92:8 ratio). 38  The selective removal of acetate from the 
anomeric group was achieved by hydrazine acetate in DMF to produce compound 3.02 which rapidly 
interconverts between the α and β forms.39  DABCO, a sterically hindered base, was utilized in the 
nucleophilic aromatic substitution of 2,4-dinitrofluorobenzene resulting in the selective formation of the 
β anomer (9:1 ratio) of 3.03 in 51-61% yield.40  The stereoseletivity of this reaction has been attributed 
to steric hindrance of 2,4-dinitrophenol which favors the equatorial position and the kinetic anomeric 
effect or the β-effect where the nucleophilicity of the alkoxide is enhanced by electron-electron 
repulsion from both lone pairs of the ring oxygen when in the equatorial position.41  Purification of the β 
from the α anomer was easily accomplished by recrystallization in ethanol.  Global deprotection of the 
acetyl groups proceeded in HCl/methanol followed by purification on silica gel and recrystallization in 
methanol-diethyl ether to give compound 3.04 in 37% yield. 
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2.1.2 Synthesis of N-alkylated Inhibitors 
The design of lead compounds to be used as competitive inhibitors of GCase would require a 
molecule structurally similar to GlcCer, a feature which may add high affinity and specificity to GCase.  
GlcCer contains a polyhydroxylated β-D-glucose scaffold with a long branching lipophilic ceramide 
moiety at the anomeric position (Scheme 1.2.3).  Inositol is a polyhydroxylated cyclohexane ring and can 
be considered a glucose mimic because of the equatorial positions of all hydroxyl groups.  To mimic the 
hydrophobic ceramide varying lengths of carbon chains could be installed onto the cyclohexane ring 
thus introducing the potential for hydrophobic interactions inside the ceramide binding site of GCase .  
Additionally, a permanently positive charge added to the inhibitor may mimic the oxocarbenium-ion like 
transition state typical of β-retaining glucosidases like GCase as well as introduce potential ionic 
interactions with the active site glutamate.  Collectively, inositol derivatives containing five hydroxyls in 
equatorial positions at C2-C6 and a positively charged amine at C1 modified with lipophillic chains of 
varying lengths could be used to evaluate the structure-activity relationships of the alkylated 
aminocyclitols with GCase.  
 Compound 3.07 was synthesized following literature procedures by heating  2,2-
dimethoxypropane in the presence of toluene sulphonic acid.42  Selective formation of the 
thermodynamically favored trans-isopropylidene was achieved at high temperature followed by cooling 
the reaction to room temperature allowing time for hydrolysis of the less stable cis-isopropylidene 
kinetic product in ethanol and diethyl ether over 2 hours.  Neutralization with triethylamine immediately 
initiates precipitation of 3.05 which is subsequently purified by recrystallization from ethanol to give 
3.05 in 62% yield.  Benzylation of 3.05 in DMF was achieved by deprotonating the remaining hydroxyl 
groups of inositol with NaH followed by nucleophilic substitution by benzyl bromide.43  Aqueous workup 
and purification on silica gel provided 3.06 in 80% yield.  Removal of isopropylidene was accomplished in 
refluxing AcOH and water followed by purification on silica gel to give diol 3.07 as a white powder in 
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66% yield.  Regioselective protection of the equatorial hydroxyl group of diol 3.07 was achieved by 
nucleophilic enhancement of the equatorial oxygen.44  The procedure begins by forming the stannylene 
complex by refluxing the compound in the presence of dibutyltin oxide in toluene using a Dean-Stark 
apparatus to remove the generated water. 45 Association of two stannylene complexes results in axial 
hydroxyl groups interacting with two tin atoms while equatorial groups interact with a single tin atom.  
This causes the equatorial oxygens to hold a greater negative charge allowing for selective nucleophilic 
substitution in the equatorial position.  Once the stannylene was formed, the toluene was removed and 
replaced with acetonitrile, a solvent which coordinates with tin in the stannylene intermediate to 
further enhance the nucleophilicity of the oxygen atoms.44  Finally, fluoride ion was added to the 
reaction as a catalyst to give 3.08 in 80% yield.44  Danishefsky,46 and later clarified by Nagashima,47 
hypothesized that the fluoride anion attacks the tin atom to form a pentacoordinated complex that can 
dissociate resulting in a highly reactive alkoxide atom in situ.48  The introduction of a nitrogen containing 
group at carbon 2 as well as conversion of the inositol from the myo to the scyllo configuration was 
achieved by mesylation of the free hydroxyl group followed by azidolysis with sodium azide in DMF.  The 
SN2 mechanism provided the scyllo-azide 3.09 at 69% yield over both steps.  Reduction of the azide with 
lithium aluminum hydride in THF provided the primary amine 3.09 in 98% yield.  Previous reports 
describe the reductive amination of the inosamine with an aldehyde in the presence of sodium 
cyanoborohydride and acetic acid.49  However, this method suffered from slow reaction times and a 
large quantity of dialkylated side product while leaving unreacted starting material.  An improved 
stepwise method was found which involved generating a large quantity of the imine by using excess 
aldehyde in methanol followed by rapid reduction of both imine and aldehyde by using the stronger 
reducing agent NaBH4. 
50  The stepwise reductive amination method prevents dialkylation and provided 
compound 3.10 at 70% yield compared to the concerted method at 25% yield.  The presence of the N-
alkylated product was confirmed by the characteristic quartet of triplets (J = 11, 7Hz) at ~δ 2.8 ppm in 
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the 1H NMR spectrum (appendix page 110) corresponding to the two hydrogens of the first carbon on 
the alkyl chain.  Global deprotection of the benzylated inosamine 3.11 using hydrogenolysis with Pd/C 
and H2 proved to be exceptionally difficult as observed with similar compounds.
51  Initial attempts 
following a published procedure52 failed to deprotect the benzyl ethers in our hands.  THF is known to 
form clathrate cages to trap hydrogen gas and promote hydrogenolysis reactions.53  Although the use of 
THF produced partially debenzylated products after several days under atmospheric pressure, the 
reaction stalled most likely due to poisoning of the Pd/C catalyst.  Despite the low yields, we were able 
to isolate small amounts of 3.12 for NMR using flash column chromatography.  Interestingly, the NMR 
spectrum appeared to confirm the structure of 3.12, however, broad peaks without distinct coupling 
patterns were obtained regardless of concentration of products and solvent choice.  We hypothesized 
that Pd may be coordinated to the inosamine ring thus affecting the NMR spectrum through line 
broadening affects.  To further investigate this hypothesis, we dissolved the isolated inosamine 3.12 in 
water followed by the addition of NH4OH, conditions known to form an insoluble (NH3)2PdCl2 complex.  
Addition of the NH4OH to compound 3.12 resulted in the formation of a dark precipitate indicating the 
presence of contaminating Pd/C.  A decrease in the overall mass by 64% resulted, corresponding to the 
loss of a single Pd/C per two molecules of 3.12.  After Pd/C removal the NMR spectrum sharpened 
considerably as shown in Figure 2.1.  Although this procedure produced 3.12 in only 25% yield, sufficient 
quantities of the aminocyclitol were obtained in order to conduct inhibitor studies.  Interestingly, the 
NMR spectra of several previously published aminocyclitols appear to suggest Pd contamination in some 
of their samples thus questioning the validity of the biological data obtained.32c, 32d, 54   
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Figure 2.1:  NMR spectra of 3.20 A) Compound hypothesized to be chelated to Pd/C. B) Compound after 
precipitation of Pd/C.  
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Scheme 2.2: Synthesis of N-alkylated Inhibitors 
 
Reagents and Conditions: (a) 2,2-DMP, TsOH, DMSO, EtOH, 90°C; then add Et2O, Et3N, rt, 62% (b) NaH, 
BnBr, DMF, 0°C – rt(c) HOAc, H2O, reflux,  53% (d) dibutyltin oxide, BnBr, CH3CN, tetrabutylammonium 
bromide, 80% (e) 1) Mesyl Chloride, pyr, rt. 2) NaN3, DMF, 85°C  69% (f) LiAlH4, Et2O, 0°C – rt. 100% (g) n-
C6H12O, NaBH3CN, MeOH 25% (h) Pd/C, MeOH, HCl, H2 (50PSI).  
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2.1.3 Synthesis of O-alkylated Inhibitors and O- and N-alkylated Inhibitors 
 Synthesis of the O- and N-alkylated inhibitors started from the racemic tetrabenzyl inositol 3.07 
shown in Scheme 2.3.  Selective alkylation of the equatorial hydroxyl group was performed using the 
dibutyltin oxide method described above.  Alkylation of the equatorial oxygen was achieved with the 
corresponding 1-bromo alkane in DMF utilizing CsF as a fluoride catalyst provided the butyl, hexyl, and 
octyl derivatives, 3.18, 3.17, and 3.16, in 60%, 74%, and 77% yields respectively.  The presence of the O-
alkylated derivative was confirmed by two characteristic doublet of triplets (J = 7, 6Hz) that can appear 
as a quartet at ~δ3.6 and ~ δ3.7 and correspond to diastereotopic hydrogens from the first carbon of the 
alkyl chain.  Conversion of the free secondary alcohol to inverted azide was facilitated by mesylation 
followed by azidolysis.  After the azidolysis reaction, reduction with LiAlH4 afforded the corresponding 
protected primary amine. Reduction of the azide and hydrogenolysis of the benzyl ethers was achieved 
by Pd/C, HCl, and MeOH with H2(g) at 50 PSI  to provide the primary amines 3.19, 3.20, and 3.21 in 70%, 
29%, and 28% yield respectively.  As observed for compound 3.12, chelation of the free aminocyclitols to 
Pd/C appeared to occur for the hexyl and butyl chain compounds 3.20 and 3.21 using NMR and the 
NH4OH precipitation method.  Interestingly, nonyl inosamine 3.19 did not appear to have sufficient 
affinity for Pd as the shorter chain derivatives which was reflected in the much higher recoverable yield 
and distinct peaks in the NMR spectrum (appendix page 116).   
To generate the O- and N-alkylated inhibitors we first reduced the azides using lithium 
aluminum hydride in THF to provide the primary amines 3.22 and 3.23 in quantitative yield.  Alkylation 
of the amine was achieved by using the two step reductive amination discussed above for compounds 
3.24-3.28.  The presence of the N-alkylated product was again confirmed by the presence of a 
characteristic quartet of triplets ( J = 11, 7Hz) at ~δ2.8ppm corresponding to the two hydrogens of the 
first carbon on the alkyl chain.  Hydrogenolysis of the benzyl ethers was achieved by Pd/C, HCl, and 
MeOH with H2(g) at 50 PSI  to provide the O- and N- alkylated compounds 3.29, 3.30, 3.31, 3.32, and 3.33 
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in 63%, 20%, 67%, 77% and 77% yield respectively.  As observed for the nonyl inosamine derivative 3.19, 
no visible precipitation of Pd/C was observed for the dialkylated compounds after the addition of 
NH4OH, demonstrating that these compounds did not form a stable complex with Pd. In addition, clear 
coupling patterns were observed in NMR spectra clearly indicating the lack of Pd contamination.  
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Scheme 2.3: Synthesis of O- and N-alkylated Inhibitors
 
Reagents and Conditions: (a) 1) Dibutyltin oxide, toluene, reflux 2) CsF, n-C8H17Br or n-C6H13Br, DMF (b) 
1) Mesyl Chloride, pyr, rt. 2) NaN3, DMF, 85°C  (c) Pd/C, MeOH, HCl, H2 (50PSI) (d) LiAlH4, Et2O, 0°C – rt. 
(e) n-C8H16O or n-C6H12O or n-C4H8O, NaBH4, MeOH (f) Pd/C, MeOH, HCl, H2 (50PSI) 
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2.2 Expression and Purification of a Model β-glucosidase ABG 
Agrobacterium sp. β-Glucosidase (ABG) is a well-studied, inexpensive and stable β-glucosidase 
often used as an initial control enzyme for evaluating novel glycosidase inhibitors.  The enzyme is readily 
produced from Escherichia coli, is accepting of unnatural colorimetric substrates and has been subjected 
to a variety of β-glucosidase inhibitor studies.10, 55  Importantly, both ABG and GCase are retaining 
enzymes and employ the double displacement mechanism relying on a pair of Glu residues in the 
enzyme active site.55a  The ABG gene was kindly provided by Dr. Stephen Withers in a pET28b expression 
plasmid that is engineered to produce a hexahistidine-tagged enzyme in Escherichia coli.   Expression 
and purification of ABG using Ni-NTA affinity column chromatography yielded pure enzyme as shown in 
Figure 2.2. 
 
Figure 2.2: SDS-PAGE of purified ABG solution.  Lanes 1 and 4) PageRuler prestained protein ladder. Lane 
2) 5 µL ABG solution. Lane 3) 10 µL ABG solution 
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2.3 Enzyme Inhibition Studies with ABG and GCase 
 All synthesized potential chaperone compounds were evaluated as competitive inhibitors of 
ABG and GCase.  Although there is no crystal structure for ABG, it is known from substrate specificity 
and inhibition studies that ABG does not possess a well-defined or large hydrophobic binding pocket 
adjacent to the active site.  Therefore, inhibitors with hydrophobic groups should have lower Ki values 
for GCase over ABG.  As a consequence, comparing inhibitor activities with ABG and GCase allows for 
insight into the reactivity and specificity of the inhibitors with the other β-glucosidases that would be 
present in a living system.  
 The concentrations of the synthetic substrate 2,4-DNP-β-D-Glc were chosen to be within a range 
(5 x KM to KM/3).  Michaelis-Menten curves were generated for each enzyme to verify that the KM is 
comparable to literature values where the KM of 2,4-DNP-β-D-Glc for ABG is 31 µM,
55a and GCase is 1.6 
mM.56  In all cases, initial rates were monitored at 400 nm and were well within the linear region of each 
time activity curve.  Each inhibitor was tested at six concentrations that were determined by using a 
crude IC50 value to estimate the Ki value.  The data was fit to the competitive inhibition equation using 
the GraphPad Prism software utilizing Equation 2.1 where V = initial velocity, KM is the Michaelis 
constant of the substrate, Vmax is the maximum reaction velocity, [I] is inhibitor concentration, [S] is 
substrate concentration and Ki is the dissociation constant for the enzyme-inhibitor complex. 
Equation 2.1:       
       
     
   
  
     
 
This equation remains valid under steady state conditions and when [S] and [I] are much greater than 
[E].  The [S] and [I] must be much greater than [E] in order to ensure that the total concentrations of [S] 
and [I] are consistent while monitoring initial enzymatic rates in the presence of inhibitor. If the 
concentrations of [S] and [I] are approaching to or less than [E], the case when assays are performed on 
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low nM level competitive inhibitors, the concentration of [I] is significantly lowered when bound to the 
enzyme.57  For all of our inhibition assays, [S] and [I] are > 10 x [E] thus fulfilling the mathematical 
requirements to solve for Ki.  Representation and analysis of competitive inhibition data was historically 
done through the use of Lineweaver-Burke transformations due to the limited availability of nonlinear 
regression algorithms and the visual appeal of the Lineweaver-Burke linear regression model.  However, 
determining Ki values requires transformation of the data from non-linear into linear representation 
which distorts experimental errors at low concentrations of inhibitor and substrate.58  This model has 
been proven obsolete due to violating assumptions of linear regression which requires uncertainty 
values to be known resulting in inaccurate calculations of slopes and intercepts.58-59  Therefore, non-
linear regression analysis with the Graphpad Prism software was used to calculate Ki values and 
associated error for all inhibitors tested in this thesis and the corresponding graphs are shown for each 
assay.  
2.3.1 Kinetic Analysis of the Inhibition of ABG and GCase by the N-alkylated Inhibitor 3.12 
 Compound 3.12 was the only inhibitor synthesized over the course of this work that was 
alkylated solely at the nitrogen of the inosamine ring.  Previous reports indicate that a series of N-
alkylated scyllo-inosamine inhibitors of various alkyl chain lengths do indeed bind to GCase with 
increasing affinity corresponding to chain length increases from 4 to 16 carbons.32b, 32c  We sought to 
synthesize an N-alkylated inhibitor to compare our compound against existing inhibitors and to validate 
our enzyme preparations and kinetic methods.  Compound 3.12 was synthesized and tested against 
GCase using competitive inhibition and yielded a Ki value that fit well within the expected range from 
the series of inhibitors that can be seen in Table 2.3.1. 
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Table 2.3.1:  Ki values and comparison of N-alkylated competitive inhibitors 
Inhibitor Structure Ki (µM) Relative Binding Affinity 
 
39.4 1 
 
17.8 ± 1.42 2.21 
 
15.5 2.54 
 
10.4 3.79 
 
1.9 20.7 
 
0.3 131 
 
0.4 98.5 
 
*Data for 3.12 came from this work, all other data came from Egido-Gabas et al.32b 
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The Ki value obtained for 3.12 follows the trend published by Egido-Gabas
32b indicating our 
enzyme kinetic assays used to evaluate our inhibitors were valid.  This was especially critical considering 
Dr. Lorne Clark from Children’s Hospital in Vancouver provided us with Cerezyme from left-over patient 
vials.  Therefore, we wanted to confirm that the enzyme preparation was fully active and properly 
stored.  The non-linear regression plot for 3.12 with ABG and GCase can be seen in Figure 2.3.1. 
When analyzing the data obtained from previously reported N-alkylated inosamines, several 
important trends emerge.  To begin, only modest improvements were observed upon increasing chain 
length from the pentyl to the octyl chains.  This indicates that the alkyl chain must be at least 8 carbons 
long to significantly occupy the hydrophobic pocket of GCase.  A second interesting point was that the 
16 carbon derivative showed lower binding affinity or an increased Ki when compared to the 10 carbon 
derivative.32b  This was an unexpected result since the length of the ceramide hydrophobic chain is 16 
carbons.  To help understand the kinetic components of binding affinity, the inhibition constant can be 
expressed as the ratio between the rate of inhibitor dissociation and the rate of inhibitor association 
(Equation 2.2).  Therefore, compounds having very low Ki values must rapidly bind to the protein and 
only very slowly dissociate away from the binding site. 
Equation 2.2:         
   
  
 
The increased Ki from the 16 carbon inhibitor with respect to the 10 carbon inhibitor would 
imply that although the dissociation of the inhibitor (k-i) may be slower through stronger binding, the 
rate at which the 16 carbon inhibitor binds (ki) was decreased resulting in the increased Ki.  However, it 
is currently unknown how GCase catalyzes the hydrolysis of the GlcCer in the natural environment with 
the help of saposin C.  It is likely that the lipid chain is partially buried in the membrane bilayer or 
saposin C during hydrolysis by GCase.  Alternatively, the 16 carbon inosamine derivative may have low 
solubility under the assay conditions used.  As a consequence, aggregation of the inhibitor and non-
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specific inhibition of GCase may occur as occasionally observed in poorly soluble compounds.60  The 
inhibition of another enzyme was not performed over the course of Delgado’s work and therefore 
aggregation of the alkylated inosamine and non-specific inhibition cannot be ruled out.  
To ensure that our compound 3.12 inhibited other β-glucosidases and did not possess a reactive 
contaminant or form inhibitor aggregates, we used ABG as a control enzyme.  As expected, 3.12 was a 
good inhibitor of ABG but not to the same extent as GCase.  In addition, the presence of the N-alkyl 
chain did not improve binding affinity when compared to the known inhibitor gluconolactone (with a Ki 
= 1.4 µM determined in our lab consistent with previously published results).55b  This data clearly 
demonstrates that the inhibitor preparation contained no reactive contaminants, did not form inhibitor 
aggregates and the assay conditions used were suitable for both GCase and ABG. 
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Figure 2.3.1:  Nonlinear regression plots of the competitive inhibitor 3.12 using the substrate 2,4-DNP-β-
D-Glc  A) Inhibition of ABG. B) Inhibition of GCase. 
2.3.2 Kinetic Analysis of the Inhibition of ABG and GCase by O-alkylated Inhibitors 3.19, 3.20 
and 3.21 
 When we were confident that ABG and GCase were producing data consistent with previous 
studies and our enzymatic assays were reliable, we next investigated the influence of alkyl chain length 
on the O-alkylated inosamine derivatives inhibitors 3.19, 3.20 and 3.21.   
A) B) 
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Table 2.3.2 Ki values and comparison of O-alkylated competitive inhibitors 
Inhibitor Structure ID GCase Ki (µM) Relative 
Affinity with 
GCase  
ABG Ki (µM) Relative 
Affinity with 
ABG 
 
3.19 7.40 ± 1.13 
µM 
11.3 93.8 ± 9.10 
µM 
9.08 
 
3.20 77.7 ± 14.0 
µM 
1.07 849 ± 131 
µM 
1.00 
 
3.21 83.3 ± 12.9 
µM 
1.00 852 ± 122 
µM 
1.00 
 
From the Ki values of the O-alkylated inosamines we observe that increasing the alkyl chain 
length corresponded to a higher affinity or a lower Ki value for GCase, similar to what was reported for 
the N-alkylated inhibitors.  The O-nonyl derivative 3.19 shows a Ki value in the low µM range, a value 
consistent with the octyl and nonyl N-alkylated derivatives.   
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Figure 2.3.2:  Nonlinear regression plots of the competitive inhibitor 3.19 using the substrate 2,4-DNP-β-
D-Glc  A)Inhibition of ABG. B) Inhibition of GCase. 
This indicates that the position of the alkyl chain in relation to the positively charged amine may 
not dramatically affect molecular recognition, suggesting that N,O-dialkylated inosamines may be very 
potent inhibitors.  As expected from the N-alkyl inhibitors, the hexyl and butyl inosamines 3.20 and 3.21 
had similar affinity toward GCase with Ki values near 80µM.   
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Figure 2.3.3:  Nonlinear regression plots of the competitive inhibitor 3.20 using the substrate 2,4-DNP-β-
D-Glc  A)Inhibition of ABG. B) Inhibition of GCase. 
A) B) 
A) B) 
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Figure 2.3.4:  Nonlinear regression plots of the competitive inhibitor 3.21 using the substrate 2,4-DNP-β-
D-Glc  A) Inhibition of ABG. B) Inhibition of GCase. 
When testing the inosamines with ABG, inhibitor 3.19 was measured to have Ki value of 93.80 
µM.  In contrast, the hexyl and butyl derivatives 3.20 and 3.21 were poor inhibitors with Ki values in the 
mM range.  We observed nearly an identical increase in the relative Ki values of the inhibitors when 
increasing chain length from the butyl/hexyl to nonyl alkyl chains for both ABG and GCase.   
It is interesting to note that for both GCase and ABG there was statistically no difference 
between the Ki values obtained for the hexyl and butyl derivatives.  This may indicate that the O-alkyl 
chain of four and six carbons in length were not sufficiently long enough to occupy the hydrophobic 
areas within both GCase and ABG and therefore associate and dissociate from the enzyme at roughly 
the same rate. However, the nonyl chain showed a large decrease in Ki for both ABG and GCase 
indicating a very tight association.  There are a number of difficulties in making structure-activity 
relationships based solely on Ki due to many possible interactions affecting Ki that cannot be accounted 
for without additional complex experiments. For example, these inositol compounds have the potential 
to form micelles.  Longer alkyl chain derivatives could form micelles at lower concentrations thus 
resulting in less accessible inhibitor and higher observed Ki values.  For our analysis we have to assume 
these additional interactions are negligible.  
A) B) 
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The Ki of the nonyl derivative 3.19 was similar in magnitude compared to the N-alkylated 
derivative.  Importantly, the N-alkylated inosamines displayed a large change in the Ki values between 
the octyl and nonyl derivatives which was similar to the difference between the O-alkylated hexyl and 
nonyl derivatives.  This dramatic change in Ki supports our hypothesis of the presence of a hydrophobic 
pocket at a location corresponding to carbons 9 and 10 of the alkyl chains within GCase.  Critically, these 
experiments indicate that derivatives having both N- and O-alkylated chains may indeed produce 
chaperones with very low Ki values, therefore warranting the synthesis and evaluation of dialkylated 
inosamines.  
2.3.3 Kinetic Analysis of the Inhibition of ABG and GCase by O- and N-alkylated Inhibitors 
3.29-3.33 
The O- and N- doubly alkylated inhibitors were expected to have the highest affinity to GCase 
due to the structural similarity to the glucocerebrosides and based on our results with the mono-
alkylated inhibitors above.  However, one significant difference is that the lipid moiety of 
glucosylceramide branches at 2 carbons away from the glucose ring in contrast to the inosamines in 
which both alkyl chains are directly attached to the inositol ring.  To evaluate our hypothesis that 
dialkylated inositols will make potent inhibitors of GCase, compounds 3.29-3.33 were tested as 
inhibitors of both ABG and GCase.  
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Figure 2.3.5:  Nonlinear regression plots of the competitive inhibitor 3.32 using the substrate 2,4-DNP-β-
D-Glc  A) Inhibition of ABG. B) Inhibition of GCase. 
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Figure 2.3.6:  Nonlinear regression plots of the competitive inhibitor 3.33 using the substrate 2,4-DNP-β-
D-Glc  A) Inhibition of ABG. B) Inhibition of GCase. 
We will start by looking at the Ki values for the various N-akylated, O-nonyl derivatives for GCase 
as shown in Table 2.3.3; all of which were very potent inhibitors of GCase.  The N-alkyl, O-nonyl 
derivatives 3.29-3.31 differ by increasing the N-chain length from butyl to hexyl to octyl.  Interestingly, 
there was no significant difference in Ki values between the octyl and hexyl chains on the N which was 
clearly observed in the N-alkylated compounds from Egido-Gabasl.32b  In contrast, the butyl inhibitor 
3.31 showed a more significant 19-fold increase in Ki from the hexyl derivative 3.30 than the 2.5-fold 
increase that was observed in the N-alkylated compounds.32b    
A) 
A) B) 
B) 
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Figure 2.3.7:  Nonlinear regression plots of the competitive inhibitor 3.29 using the substrate 2,4-DNP-β-
D-Glc  A) Inhibition of ABG. B) Inhibition of GCase. 
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Figure 2.3.8:  Nonlinear regression plots of the competitive inhibitor 3.30 using the substrate 2,4-DNP-β-
D-Glc  A) Inhibition of ABG. B) Inhibition of GCase. 
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Figure2.3.9:  Nonlinear regression plots of the competitive inhibitor 3.31 using the substrate 2,4-DNP-β-
D-Glc  A) Inhibition of ABG. B) Inhibition of GCase. 
The N-octyl, O-hexyl derivative 3.32 was found to be a 2.5-fold better inhibitor than the N-butyl, 
O-nonyl inhibitor 3.31.  Interestingly, the N-butyl, O-hexyl inhibitor 3.32 was significantly less effective 
than the other dialkylated inhibitors and only slightly better than the N-butyl compound from Egido-
Gabas32b demonstrating the need for alkyl chain lengths to be at least 8 carbons long to significantly 
occupy the hydrophobic pocket of GCase.  Generally, increasing the O-alkyl chain length from six to nine 
carbons gives a 10-fold decrease in Ki value which corresponds to the same 10-fold decrease in Ki value 
observed in the singly O-alkylated inhibitors.  However, increasing the N-alkyl chain length from four to 
eight carbons gives a 25-fold decrease in Ki value which does not compare to the 3.8-fold decrease in Ki 
value observed in the singly N-alkylated inhibitors.  From this data, there is a dependent relationship 
between the length of the N-alkyl chain and the O-alkyl chain while the influence of the O-alkyl chain 
remains independent of the N-alkyl chain.  This suggests that binding of the O-alkyl chain may indirectly 
influence the binding site for the N-alkyl chain thereby modifying its binding affinity.  The design of 
future dialkylated inosamine inhibitors should take advantage of this relationship by further increasing 
the N-alkyl chain length in order to see the greatest change in Ki values.  
When testing the inhibitors with ABG, the inosamines 3.29-3.32 show Ki values in a range of 23-
59 µM while inhibitor 3.33 has a significantly higher Ki value of 201.6 µM.  The N-alkyl, O-nonyl 
A) B) 
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inosamines 3.29-3.31 show no significant difference in Ki values between the butyl and hexyl derivatives, 
but a 2-fold difference from the octyl derivative.  Surprisingly, the N-octyl, O-hexyl inosamine 3.32 was 
found to have a lower Ki value than N-octyl, O-nonyl inhibitor 3.29.  The lower Ki value of 3.32 can be 
explained by the lack of a well-defined hydrophobic binding pocket in ABG to accommodate the O-alkyl 
groups while there are N-alkyl groups also present and thereby decreasing binding affinity through steric 
hindrance.  Therefore, the general trend for the N-octyl, O-alkyl inhibitors is a reversal of the trend 
shown by the singly O-alkylated inhibitors, where the O-alkyl chain lengths above 6 carbons increase Ki 
values.   
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Table 2.3.3:  Ki values and comparison of O- and N-alkylated competitive inhibitors 
Inhibitor Structure ID GCase Ki (µM) ABG Ki (µM) 
 
3.29 0.102 ± 0.0150 26.6 ± 3.87 
 
3.30 0.135 ± 0.0171 47.0 ± 9.92 
 
3.31 2.60 ± 0.29 59.0 ± 9.75 
 
3.32 1.04 ± 0.121 23.0 ± 5.83 
 
3.33 28.3 ± 4.15 201 ± 26.4 
 
2.3.4 Conclusions and Future Work 
In summary, one N-alkylated compound, 3.12, three O-alkylated compounds, 3.19, 3.20, and 
3.21, and five N- and O- doubly alkylated compounds, 3.29-3.33, were synthesized as novel 
aminocyclitol inhibitors.  All aminocyclitols were evaluated for their ability to competitively inhibit GCase 
and ABG through measurement of their Ki values.  Trends between the alkyl chain length and binding 
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affinity were found showing that increasing alkyl chain length lowers Ki in each case.  The most effective 
inhibitors synthesized, 3.29 and 3.30, gave exceptionally low Ki values of 101.9 and 135.0 nM 
respectively suggesting that these structures are excellent lead compounds for the design of more 
advanced chemical chaperones.  In addition, these compounds are potent inhibitors to warrant 
chaperoning studies using cell lines that express mutant GCase.21, 32b, 54  
2.3.5 Special Note 
 During the second year of this project, similar dialkylated aminocyclitol compounds were 
synthesized and evaluated as chemical chaperones for GCase published by Ana Trapero et al.32d  In this 
study, the authors reported aminocyclitols bearing two nonyl chains both in the myo- and scyllo-
configuration confirming that the dialkylated inosamines are indeed potent inhibitors of GCase and were 
effective at raising lysosomal levels of mutant enzyme.  Interestingly the myo-derivative had a 
remarkable Ki of 1nM despite having an axial substituent on the cyclohexane ring which is not found in 
the substrate GlcCer.  This suggests GCase preferentially binds to inosamines in the myo-configuration 
and these structures, in contrast to the expected scyllo-configured isomers, may be best suited as 
pharmacological chaperones of GCase.   
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Part B: Mechanism-based Aziridine Glucocerebroside Inhibitors 
3.1 Introduction 
3.1.1 Covalent Glycosidase Inhibitors 
 Covalent or suicide inhibitors are molecules that irreversibly inhibit enzyme activity by forming a 
covalent bond with the amino acid residues required for catalysis thereby causing enzyme inactivation. 
Covalent inhibitors have been used extensively to further our understanding of glycosidase enzymology 
and biochemistry, to identify active site residues, elucidate catalytic mechanisms and to study the effect 
of selectively inactivating the enzyme in a living system.  Covalent inhibitors can be further categorized 
into affinity labels or mechanism-based inhibitors.61   Affinity labels are substrate analog inhibitors that 
contain a highly reactive aglycone.  Nucleophilic attack of the electrophilic portion of the affinity label 
usually occurs within the active site at one of the enzyme’s catalytic residues.  This leads to the release 
of a highly reactive aglycone that covalently bonds to amino acid residues in the nearby region 
inactivating the enzyme.61  The aglycone released from affinity labels can be inherently chemically 
reactive or can be induced with secondary effects like with photo-reactive labels.  Two examples of 
affinity labels can be seen with 4-difluoromethylphenoxy-β-D-glucose and 2-chloro-1,1,2-
trifluoroethoxy-α-D-glucose (Scheme 3.1.1). 
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Scheme 3.1.1: Mechanism of formation of reactive aglycone from affinity labels A) Aglycone 4-
(fluoromethylene)cyclohexa-2,5-dienone from 4-difluoromethylphenoxy-β-D-glucose, B) Aglycone 2-
chloro-2-fluoroacetyl fluoride from 2-chloro-1,1,2-trifluoroethoxy-α-D-glucose.  Adapted from Rempel 
and Withers.61 
Mechanism-based inhibitors are stable to spontaneous decomposition but will react with active 
site  residues to form a covalent bond after partial processing by the enzyme’s normal catalytic 
mechanism.61  Nucleophilic attack of an electrophilic portion of the mechanism-based inhibitor occurs 
within the active site thus inactivating the enzyme.  Mechanism-based inhibitors have proven to be 
valuable tools for identifying the active site residues and elucidating the catalytic mechanism of 
glycosidases by radioactive labelling the inhibitors and sequencing the radioactive peptides.61  Examples 
of well-studied mechanism-based β-glucosidase inhibitors and their inactivation mechanisms can be 
seen with conduritol-β-epoxide and 2-deoxy-2-fluoro-β-D-glucosyl fluoride (Scheme 3.1.2).  For many 
covalent inhibitors of glycosidases, the formation of the glycosyl-enzyme intermediate is an irreversible 
A) 
B) 
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process.  For example, the spontaneous hydrolysis reactivation half-life of 2-deoxy-2-fluoro-β-D-
glucosyl-enzyme intermediate covalently bound to human GCase is 1300min-1.62  However, catalytic 
activity of the inactivated enzymes can be restored through hydrolysis of the covalently bound glycosyl-
enzyme species or through transglycosylation onto a suitable acceptor substrate.61   
 
Scheme 3.1.2: Mechanism of mechanism-based inhibitors A) conduritol-β-epoxide with β-glucosidase, 
B) conduritol-β-epoxide with α-glucosidase, C)2-deoxy-2-fluoro-β-D-glucosyl fluoride with β-glucosidase.  
Adapted from Rempel and Withers61 
A) 
B) 
C) 
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 In addition to identifying active site residues and catalytic mechanisms, covalent inhibitors can 
also be used to label enzymes to monitor intracellular trafficking or the biodistribution of enzymes 
injected into living animals or humans.  Knowledge of the biodistribution of recombinant enzymes in 
enzyme replacement therapy (ERT) is vital to determine its ability to target specific tissues and the tissue 
half-lives in order to improve the design of the enzyme and provide the most effective treatment.63  
Standard biodistribution monitoring procedures typically involve covalent inhibitors called activity 
based-probes that contain a labelling molecule such as a fluorophore or affinity tag.64  The probes are 
introduced to cell lysates, cell systems, or animal models and subsequently analyzed by fluorescence or 
mass spectroscopy to determine the extent of enzyme uptake within the target cells.64   
The major drawback of using fluorescent activity based probes involves limitations in the 
detection techniques due to the shallow depth that the probes can be analyzed within tissues.  
Therefore, tissues from multiple organs and locations must be biopsied in to determine biodistribution 
in humans.  A potential solution is to use nuclear-based techniques such as PET which enable whole 
body imaging thereby providing substantially more information on the biodistribution of the enzymes in 
vivo in a single experiment.  However, introducing a positron emitting label during protein synthesis is 
impossible due to the short half-life of commonly used isotopes such as 18F (109.8min) and surface 
attachment of radiolabelled prosthetic groups, antibodies or peptides may alter the biodistribution and 
biological activities of the enzymes in vivo.63  An alternative method is to radioactively label an enzyme 
with an 18F labelled mechanism-based inhibitor and use PET to determine the biodistribution. Indeed, 
this strategy was successfully demonstrated with the recombinant enzyme Cerezyme®.63  The work 
involved synthesis of an 18F labelled mechanism-based inhibitor, 2,4-dinitrophenyl-2-deoxy-2-[18F]-
fluoro-β-D-glucopyranoside, that covalently labelled the active site of the recombinant GCase.  Since no 
significant conformational changes can be detected in the 2-fluoroglucosyl-enzyme intermediate by X-
ray crystallography,4b the normal biodistribution of the enzyme can be followed in vivo.  However, the 
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labelling agent used in this report failed to produce sufficient levels of 18F labelled Cerezyme required for 
human imaging due to slow labelling rates of the enzyme.  This required extended incubation times 
incompatible with the short half-life of the 18F isotope.  In addition, a highly efficient and specific 
inhibitor may enable the in vivo molecular imaging of GCase activity to assess Cerezyme therapy or act 
as a potential diagnostic for Gaucher disease.   
Chapter 4: Results and Discussion 
4.1 Synthesis 
4.1.1 Synthesis of Aziridine Inhibitors 
Based on the success of the aminocyclitols as inhibitors of GCase, we sought to adapt this 
chemistry to synthesize alkylated conduritol aziridines that we hypothesized to be efficient mechanism-
based inhibitors of β-glucosidases.  Synthesis of the aziridine inhibitor began from racemic tetrabenzyl 
inositol 3.07 and is shown in (Scheme 4.1).  Both the equatorial and axial oxygens of the tetrabenzyl 
3.07 were activated through mesylation using methanesulfonyl chloride in pyridine.  Regioselective 
azidolysis of the axial mesyl group at C2 proceeded smoothly, most likely due to steric hindrance 
provided by the equatorial benzyl groups to facilitate preferential attack of the free equatorial site by 
the SN2 reaction to give the desired azido mesylate 3.34 in 42%.
65 Intramolecular cyclization occurs 
presumably in a similar method to those described66 where reduction of the azide by lithium aluminum 
hydride evolves N2 (g) leaving the negatively charged nitrogen to attack the adjacent carbon to form the 
aziridine 3.35 in 60% yield. Formation of the aziridine structure was evident by NMR spectroscopy which 
displayed the unique doublet at δ2.33 (J = 6Hz) and doublet of doublets at δ 2.55 (J = 6, 3Hz) 
corresponding to H1 and H6, typical of bicyclic [4.1.0] aziridine compounds.67  Attempts at alkylation of 
the aziridine following the reductive amination procedure for primary amines in the presence of sodium 
cyanoborohydride and acetic acid failed.49 An alternative method of alkylation was pursued by refluxing 
the iodoalkane in a DCM-50% NaOH mixture with a phase transfer catalyst tetrabutylammonium 
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chloride but suffered from poor yields while leaving unreacted starting material.68  Alkylation of the 
aziridine was achieved by using potassium carbonate and the corresponding 1-iodoalkane in DMF to 
provide the octyl, hexyl and butyl derivatives in 59%, 66%, and 55% yields respectively.  Reactions 
involving the derivatization of the aziridine nitrogen are limited due to the reactivity of the highly 
strained aziridine ring.69  Consequently, global deprotection of the benzyl ethers failed using similar 
conditions described for the above compounds.  Initial attempts using Pd/C, HCl, and MeOH with H2 (g) at 
50 PSI resulted in the complete loss of starting materials resulting in unidentified amines.  Aziridines 
have been shown to have increased sensitivity to nucleophilic attack under acidic conditions,70 however 
the hydrogenolysis reaction performed in the absence of HCl did not improve the outcome.  It has also 
been previously shown that hydrogenation of aziridines with Pd/C in ethanol can cause ring opening and 
rearrangement71 so a similar competing reaction may have occurred. NMR and mass spectroscopy of the 
products of hydrogenolysis with Pd/C did not correspond to the ring opening by nucleophilic attack of 
water or methanol, or any elimination product.  Adjusting the pressure, pH, solvents, length of reaction 
and combinations of conditions afforded no improvements.  Therefore an alternate route for 
hydrogenolysis through Birch reduction was attempted.  Access to NH3 (g) was limited due to high costs, 
however commercially available alkali metals impregnated on silica gel (M-SG) had been shown to 
perform Birch reduction-like reactions under mild conditions.72  The simple procedure requires stirring 
the compound in the presence of the non-pyrophoric stage I Na2K-SG which should have the reactivity 
equivalent to neat alkali metals73 in anhydrous THF at room temperature, however, no reaction was 
observed for the protected aziridines.  Modifications to the procedure including increased quantities of 
Na2K-SG and increased temperature failed promote the reduction.  Finally, a cost effective method for 
the production of NH3 (l) necessary for Birch reduction was developed where concentrated NH4OH was 
gently heated to release NH3(g). The NH3(g) gas was then passed through several water condensers and 
drying tubes containing CaSO4 before being collected into the reaction vessel using a dry ice condenser.  
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There was potential for destruction of the compound due to base-catalyzed eliminative ring opening 
that can occur with aziridines in the presence of superbases69 so minimizing the reaction time was 
desired.  Birch reduction of a tribenzylated iminosugar showed near instantaneous removal of the 
benzyl ethers as the reaction was quenched immediately after addition of the compound to the 
reductive solution.74  Initial attempts with protected aziridine 3.41 displayed no observable deprotection 
when immediately stopping the reaction after addition.  Reaction times of 5, 10 and 15 minutes did not 
improve the reaction yield, however quantitative recovery of the starting material suggested stability of 
the protected aziridines under these harsh conditions.  A four hour reaction was attempted resulting in 
the complete consumption of starting material and a yield of 55%, 44% and 75% for the octyl, hexyl and 
butyl compounds 3.39, 3.40, 3.41 respectively following column chromatography.   
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Scheme 4.1: Synthesis of Aziridine Inactivators 
Reagents and Conditions: (a) 1) Mesyl Chloride, pyr, rt. 2) NaN3, DMF, 85°C. (b) LiAlH4, ether, 0 – rt. (c) 
K2CO3, C8H17I or C6H13I or C4H9I, DMF, 50°C. (d) Na(s), NH3(l), THF, -78°C.  
4.2 Kinetic Analysis of the Irreversible Inhibition of ABG and GCase by Aziridine Inhibitors 
3.39-3.41 
 There are a number of known covalent and mechanism based irreversible inhibitors of GCase 
including activated fluorosugars,75 conduritol aziridine, gluconolactone, cyclophellitol and conduritol 
epoxide.31a   The epoxides and aziridines are mechanism based inhibitors that are protonated or become 
protonated in the active site to increase reactivity towards nucleophilic attack by a catalytic nucleophile 
leading to covalent binding within the active site of the enzyme.67  To introduce specificity towards 
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GCase, we decided to synthesize aziridines alkylated with lipid chains which we hypothesized would lead 
to efficient, specific, and cell membrane permeable GCase inhibitors (Scheme 4.2).  
 
Scheme 4.2:  Hypothesized mechanism of the inhibition of GCase by alkylated conduritol aziridine.  R = 
butyl, hexyl, or octyl.  
To determine the rate of enzyme inactivation, a range of eight concentrations of the inhibitor 
predicted to surround the Ki value were incubated with either GCase or ABG and the reaction mixtures 
were assayed for residual enzyme activity at different time intervals.  Small aliquots of the inactivation 
solution were withdrawn and diluted 20-fold in 96 well plates containing 2 x KM of the substrate 2,4-
DNP-β-D-Glc.  Dilution of the reaction mixture effectively halts further inactivation by diluting the 
inhibitor and active site competition by excess substrate.  The velocity data was fit to the one phase 
decay equation using the GraphPad Prism software utilizing Equation 4.1. 
Equation 4.1:          –          
                  
Using Equation 2.3 gives the observed rate constant of inactivation (Kobs).  Kobs values can be 
plotted against inactivator concentration and fit to one of two equations, Equation 4.2 or Equation 4.3.  
Equation 4.2          
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Equation 4.3          
     
  
 
Scheme 4.3: General scheme for enzyme kinetics involving an irreversible mechanism-based inhibitor. 
 
 In Scheme 4.3 ki is the rate constant for inactivation, and Ki is the dissociation constant for the 
Enzyme-Inhibitor complex (k-1/k1).  Inactivation data follows Equation 4.2 when saturation of the 
enzyme occurs at high inhibitor concentrations and allows for separation of ki and Ki values.  The data 
will have an observable curve when the equation can be used effectively.  In cases where saturation 
cannot be observed due to rapid inactivation of the enzyme at high concentrations of inhibitor, the data 
will appear linear and Equation 4.3 must be used which gives the second order rate constant as the ratio 
of ki to Ki.  All of the inhibitors followed Equation 4.2 with ABG and followed Equation 4.3 with GCase.  
The kinetic analysis of the aziridine inhibitors can be seen in Figures 4.2.1-4.2.6. 
 Previous work using conduritol aziridine found that it was an efficient mechanism-based 
inhibitor of β-glucosidase from Agrobacterium faecalis (previously Alcaligenes faecalis) (pABG5, Ki = 3.0 
mM and ki = 0.077 min
-1), α-glucosidase from yeast (Ki = 9.5 mM and ki of 0.39 min
-1),67 and β-D-
glucosidase from almonds (IC50 = 0.22 µg/mL).
76  However, conduritol aziridines have never been tested 
on GCase or ABG.  
4.2.1 Inactivation rates of ABG with Inhibitors 3.39, 3.40 and 3.41 
The kinetic plot for the butyl derivative 3.41 with ABG clearly demonstrates that the butyl 
aziridine is an efficient inactivator of this enzyme with Ki = 3795 µM and ki = 0.05250 min
-1.  As shown in 
Figure 4.2.1, full inactivation of ABG required high concentrations of inhibitor approaching the solubility 
limits of the aziridine and long incubation times.  This results in an incomplete plot of kobs versus 
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concentration of inhibitor and less accurate values for Ki and ki.  In comparison to the O-butyl inosamine 
3.21, and assuming that k1 and k-1 are much larger than ki, the butyl aziridine has less binding affinity 
towards ABG having a 4.5 fold increase in the Ki value.   
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Figure 4.2.1: Inactivation of Abg with 3.41. a) Plot of remaining enzyme activity over time at the 
indicated inhibitor concentrations fitted to a one phase decay equation. b) Plot of the observed rate 
constants of inactivation versus the concentration of inhibitor.  
The next compound we assessed was the hexyl derivative 3.40.  As shown in Figure 4.2.2, this 
compound had a much lower Ki value of 572.2 µM corresponding to a 6.6 fold decrease in Ki in 
comparison to the butyl derivative which had a Ki value of 3795 µM.  The significant improvement in the 
Ki value by extending the chain from butyl to hexyl shows that the alkyl chain of the hexyl aziridine was 
sufficiently long enough to occupy the hydrophobic pocket of ABG, differing from the O-alkylated 
inhibitors that required alkyl chains longer than six carbons.  In comparison to the N-hexyl inosamine 
3.12 and O-hexyl inosamine 3.20, the hexyl aziridine has an intermediate binding affinity towards ABG 
giving a 4 fold increase in Ki value from 3.12, and a 1.5 fold decrease in the Ki value from 3.20.   
B) A) 
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Figure 4.2.2: Inactivation of Abg with 3.40. a) Plot of remaining enzyme activity over time at the 
indicated inhibitor concentrations fitted to a one phase decay equation. b) Plot of the observed rate 
constants of inactivation versus the concentration of inhibitor.  
When alkyl chain length is increased to eight carbons, as in inhibitor 3.39, we see a 2 fold 
decrease in Ki compared to the hexyl derivative 3.40 with a Ki of 282.5µM; a less substantial decrease in 
Ki than observed between the butyl and hexyl aziridine derivatives 3.40 and 3.41 (Figure 4.2.3).  This 
relative change in Ki value is much less than was found with the O-hexyl and O-nonyl inosamines 3.19 
and 3.20.  In comparison with the O-nonyl inosamine 3.19, the octyl aziridine has less binding affinity 
towards ABG with a 3 fold increase in the Ki value. 
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Figure 4.2.3: Inactivation of Abg with 3.39. a) Plot of remaining enzyme activity over time at the 
indicated inhibitor concentrations fitted to a one phase decay equation. b) Plot of the observed rate 
constants of inactivation versus the concentration of inhibitor.  
B) A) 
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In summary, the Ki values of the aziridine inhibitors with ABG followed the general trend of 
decreasing Ki values or improving binding affinity as alkyl chain length increases.  However, the 
measured Ki values of the aziridines were much higher or had lower affinity to ABG when compared to 
the reversible inosamine inhibitors of identical chain length.  This observation may be due in part to the 
pKa of the nitrogen of the alkylated aziridines at the pH used for the ABG assay which was 6.8.  Although 
we did not determine the pKa of our alkylated aziridines, previous reports indicate that the conjugate 
acid of the unalkylated aziridine has a pKa of 7.98.
69  Since the pKa of the secondary amine 
dimethylamine is 10.68 and the tertiary trimethylamine is 9.80, the pKa of the alkylated aziridine may be 
approximately 7.1.  Therefore, in the ABG assay buffer (pH 6.8) a significant percentage of the inhibitor 
would be present as the neutral amine.   This could potentially explain the lower affinity of the aziridines 
towards ABG in comparison to the alkylated inosamine described in Part A.  The inactivation rate (ki) of 
each aziridine with ABG remained roughly the same magnitude of 0.1 min-1 for all inhibitors.  This value 
is comparable to the measured inactivation rate constant of conduritol inositol determined to be a ki 
value of 0.077 min-1 with pABG5.67   
4.2.2 Inactivation Rates of GCase with Inhibitors 3.39, 3.40 and 3.41 
 With each of the alkylated aziridines synthesized in this work, rapid inactivation of GCase 
prevented us from determining the individual Ki and ki values.  This is because at saturating 
concentrations of inhibitor, the enzyme is almost instantaneously inactivated.  For example, the least 
reactive butyl derivative completely inactivated GCase at 100µM in ~10 minutes.  As a result, we could 
only determine the second order rate constant ki/Ki, a parameter still useful to rank the efficiency of the 
various inactivators of GCase.   
The butyl aziridine 3.41 is a highly efficient inactivator of GCase with an impressive ki/Ki = 3.837 
mM-1min-1.  As shown in Figure 4.2.4, full inactivation of GCase could be achieved using relatively low 
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concentration of 100 µM inhibitor in ~10 minutes.  To allow for comparisons to the competitive 
inhibitors, we can approximate the ki value to the value obtained for ABG (~0.1min
-1) which gives an 
approximate Ki value for 3.41 of 26 µM.  This approximate Ki value would be moderately better than the 
Ki values obtained with the N-butyl and O-butyl inhibitors indicating improved binding affinity with the 
butyl aziridine inhibitor. 
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Figure 4.2.4: Inactivation of GCase with 3.41. a) Plot of remaining enzyme activity over time at the 
indicated inhibitor concentrations fitted to a one phase decay equation. b) Plot of the observed rate 
constants of inactivation versus the concentration of inhibitor.  
The hexyl aziridine 3.40 is an exceptionally potent inhibitor of GCase with a ki/Ki = 645.4 mM
-
1min-1.  As shown in Figure 4.2.5, full inactivation of GCase could be achieved using the low 
concentration of 1.6 µM in less than 5 minutes.  If we approximate the ki value to the value obtained for 
ABG (~0.1min-1), we obtain a Ki value for 3.40 of 154 nM.  This approximate Ki value would be far better 
than the Ki values obtained with the N-hexy and O-hexyl inhibitors indicating significantly improved 
binding affinity with the hexyl aziridine inhibitor.  
 
B) A) 
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Figure 4.2.5: Inactivation of GCase with 3.40. a) Plot of remaining enzyme activity over time at the 
indicated inhibitor concentrations fitted to a one phase decay equation. b) Plot of the observed rate 
constants of inactivation versus the concentration of inhibitor.  
The octyl aziridine is the most potent aziridine inhibitor tested with GCase, providing a 37.5 fold 
better ki/Ki of 3674 mM
-1min-1 (Figure 4.2.6).  For comparison purposes, the well-studied mechanism-
based inactivator of GCase 2-deoxy-2-fluoro-β-D-glucosyl fluoride has a ki/Ki of 0.0227mM
-1min-1 62 while 
the Dioctyl (2-deoxy-2-fluoro-β-D-glucopyranosyl) phosphate is the best reported inactivator of GCase 
with a ki/Ki of 98mM
-1min-1.56  The octyl derivative 3.39 is capable of near complete inactivation of GCase 
within 40 minutes at equimolar concentrations and complete inactivation in 20 minutes at 1.5 x 
concentration.  In comparison, the same amount of Dioctyl (2-deoxy-2-fluoro-β-D-glucopyranosyl) 
phosphate would require 1600 minutes and 800 minutes for the same levels of inactivation in GCase.  If 
we approximate the ki value to the value obtained for ABG (~0.1min
-1), we obtain an approximate Ki 
value for 3.39 of 27 nM.  This approximate Ki value would be significantly better than the Ki values 
obtained with the N-nonyl and O-nonyl inhibitors.  
B) A) 
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Figure 4.2.6: Inactivation of GCase with 3.39. a) Plot of remaining enzyme activity over time at the 
indicated inhibitor concentrations fitted to a one phase decay equation. b) Plot of the observed rate 
constants of inactivation versus the concentration of inhibitor.  
To test for a highly reactive impurity in the inhibitor preparations, experiments were performed 
using concentration of the enzyme approaching the concentration of inactivator.56  Based on the NMR 
spectra of compounds 3.39-3.41, we can safely assume that the aziridine purity was ≥ 95%.  Therefore, if 
inhibitor preparations were to contain a reactive but trace contaminant that was inactivating the 
enzyme, this compound would be at very dilute concentrations (i.e. a maximum value of 5% relative to 
the aziridine inhibitor).  If the concentration of enzyme is greater than the trace impurity and complete 
inactivation of the enzyme is still observed in short reaction times, then the contaminant cannot be 
responsible for the inactivation.  All aziridines synthesized in this thesis were incubated at stoichiometric 
levels of enzyme leading to the expected level of inactivation indicating that the aziridines were indeed 
responsible for the observed inhibition. 
In summary, the aziridine derivatives were potent inhibitors of GCase following the general 
trend of improved inactivation rates as alkyl chain length increases (summarized in Table 4.2.1).  This 
B) A) 
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change in ki/Ki values was much more pronounced than what was observed for the reversible 
competitive inhibitors and enzyme inactivation can be attributed solely to the aziridine inhibitors.  
Table 4.2.1:  Ki and ki values and comparison of GCase inactivators 
Inhibitor Structure ID ABG ki/Ki 
(mM-1min-1) 
Relative 
Change 
ABG 
GCase ki/Ki 
(mM-1min-1) 
Relative 
Change 
GCase 
 
3.41 .0138 1 3.84 ± 
0.0972 
1 
 
3.40 0.241 17.42 645 ± 30.6 168 
 
3.39 0.346  25.01 3670 ± 72.0 958 
 
2-deoxy-2-
fluoro-β-D-
glucosyl 
fluoride 
12.6 911 0.0227 0.00592 
 
 
Dioctyl (2-
deoxy-2-fluoro-
β-D-
glucopyranosyl) 
phosphate 
17 1229.2 98 26 
 
4.2.3 Turnover of the Inhibitor-Enzyme Covalent Intermediate 
β-Glycosidases inactivated by mechanism based inhibitors can reactivate by spontaneous 
hydrolysis of the covalent enzyme-inhibitor complex or by transglycosylation of the inhibitor onto an 
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acceptor sugar.4b  It is important to know the reactivation rates for our inhibitors in order to ensure they 
remain covalently bound sufficiently long enough to function as persistent inhibitors for cell studies, as 
activity based probes for analyzing GCase activity in complex mixtures, and as labelling agents for PET 
imaging.  Reactivation of GCase was measured by completely inactivating GCase in a minimal 
concentration of the aziridine followed by removal of the free inhibitor using a desalting column.  The 
inactivated enzyme was then incubated in assay buffer with high levels of 2,4-DNP-Glc and continuously 
monitored over 12 hours.  Only spontaneous hydrolysis of the 2,4-DNP-Glc was observed over the entire 
12 hour time period indicating that the aziridine-GCase covalent intermediate is very stable and no free 
enzyme is regenerated.  These results are expected because no reactivation was observed in pABG5 
inactivated with conduritol aziridine.67  For comparison purposes, the fluorosugar 2-deoxy-2-fluoro-β-D-
glucosyl fluoride, which forms a 2-fluoroglucosyl-GCase intermediate, reactivates with a 1300 minute 
half-life indicating that the aziridine compounds have enormous potential as irreversible inhibitors and 
labeling agents for both cell and in vivo studies.75 
4.2.4 Kinetic Analysis of the Inactivation of GCase in Cell Lysates by Aziridine Inhibitors 3.39-
3.41 
 To test the efficacy of the aziridine inhibitors in a cellular environment and to determine if the 
inhibitors are cell membrane permeable, a cell based assay was performed.  HeLa cervical cancer cells 
were seeded into 16 well plates and grown to 80% confluency in media containing DMEM supplemented 
with 10% serum.  The aziridine inhibitors were then incubated with the cells overnight at concentrations 
of 10 nM, 100 nM and 1 µM.  The following day, the cells were washed, lysed and the supernatant 
stored at -80°C until needed.  In addition to GCase, cells can contain four isoforms of  GCase called 
GBA1, GBA2 and GBA3, as well as NLGCase, and a broad-specificity β-glucosidase.77  Due to the presence 
of these competing β-glucosidases in cell lysate preparations, conditions were carefully chosen biased 
towards GCase activity.  This included the addition of the anionic detergent sodium taurocholate as well 
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lysate absorbance relative to untreated controls and the error bars are the standard deviations based on 
three experiments.  
 We therefore decided to try two separate experiments using 0.2% and 1.2% sodium 
taurocholate in the assay buffer.  As shown in Figure 4.2.8 the sodium taurocholate did indeed affect 
the total β-glucosidase activity in cell lysates. The total β-glucosidase activities in the untreated lysates 
were 59212 AU and 79043 AU for 1.2% and 0.2% sodium taurocholate respectively (Figure 4.2.7).  The 
change in absorbance results from the increase in GCase activity and decrease in β-glucosidase activity 
indicating non-specific glucosidase activity was decreased more than GCase activity was stimulated. 
 For the butyl derivative 3.41 in 1.2% sodium taurocholate, a slight inhibition of β-glucosidase 
activity at 10 nM was observed leaving 91% residual β-glucosidase activity.  Increasing the concentration 
to 100 nM showed greater inhibition of the β-glucosidases but still left 76% of the remaining activity.  
However, when the inhibitor concentration was increased to 1 µM, a much stronger inhibition resulted 
with 44% residual β-glucosidase activity.  As expected from the kinetic data, the butyl derivative was the 
least effective inhibitor.  The hexyl derivative 3.40 inhibited ~50% of the β-glucosidase activity at 10 nM 
and 100 nM concentration.  When concentration of 3.40 was increased to 1 µM, the hexyl aziridine 
effectively inhibited β-glucosidase activity with 37% remaining activity.  The nonyl derivative 3.39 was 
expected to the most potent inhibitor based on our kinetics studies but showed no significant difference 
from the hexyl derivative 3.40 at 10 nM and 100 nM inhibitor concentrations.  However, we observed 
the highest inhibition of the β-glucosidases by inhibitor 3.39 at 1 µM concentration where only 27% 
residual β-glucosidase activity remained after treatment.  At 1 µM inhibitor concentration, the residual 
β-glucosidase activity corresponded to the kinetic data for inhibitors 3.41, 3.40 and 3.39 showing 44%, 
38%, and 26% residual enzyme activity respectively.  At lower concentrations the efficacy of the hexyl 
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and octyl derivatives 3.40 and 3.39 are similar while the butyl derivative 3.41 is clearly a less effective β-
glucosidase inhibitor.  
It is difficult to determine the degree of selectivity that the aziridines inhibit GCase over the 
other glycosidases in the cell lysates using these assays conditions.  In addition, the presence of multiple 
β-glucosidases whose expression and catalytic activity is unknown in HeLa cells can dramatically affect 
the resulting cell studies.  It is also unclear if the cell permeability of each compound significantly differs 
thereby influencing the intracellular concentration of the inhibitor and affecting inactivation rates.  
However, we can conclude that cells treated with the aziridine inhibitors produce cell lysates with 
significantly lower GCase activity, clearly demonstrating that the aziridine inhibitors are efficient and cell 
permeable inactivators of GCase.  These compounds have enormous potential as mechanism-based 
inactivators of GCase for cell studies, GCase labeling agents or lead compounds for advanced molecular 
imaging probes to assess GCase activity in vivo.  
4.3 Conclusions and Future Work 
 Further experimentation is required to determine the selectivity of the aziridine inhibitors 
towards GCase over β-glucosidases in human cells.   This can be easily accomplished by designing 
fluorescent aziridines to label the various glucosidases separated by SDS-PAGE. Additionally, cell studies 
at low temperatures will be necessary to determine if the inhibitors enter the cells through spontaneous 
cell permeability or active transport.   Modifications to the inhibitors such as increased alkyl chain 
lengths or additional functional groups could then be made to increase the efficiency, specificity, and 
cell membrane permeability of the inhibitors. Finally, labelling the aziridines with 18F can allow tracking 
of Cerezyme to explore biodistribution of the enzyme and assess ERT using PET.  
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Chapter 5: Experimental  
5.1 General Considerations: 
 All buffers and reagents were obtained from Fisher Scientific or Sigma-Aldrich without further 
purification.  Synthetic reactions were monitored by TLC using precoated silica gel plates (Silicycle 60F254, 
0.25mm thickness).  Compounds were detected by ultraviolet light ( = 254nm) followed by visualization 
with ammonium molybdate (10% w/v in 2M H2SO4), permanganate (1% w/v in water), or ninhydrin 
(1.5% w/v solution in butanol), each with heating. Flash chromatography was performed using Silicyle 
silica gel (230-400 mesh).  NMR spectra were obtained using a Varian Unity Inova 500 MHz 
spectrometer dissolving samples in the appropriate deuterated solvents (CDCl3, CD3OD or D2O). 
Chemical shifts were reported in ppm downfield from tetramethylsilane. Low resolution ESI mass 
spectrometry was performed on a Dionex UHPLC Bruker amaZon X Ion Trap Mass Spectrometer. 
3.01 1,2,3,4,6-Penta-O-acetyl-β-D-glucopyranose 
  
A solution of D-glucose (3.00 g, 16.7mmol) in anhydrous pyridine (30mL) was cooled to 0°C in an 
ice bath under argon. Acetic anhydride (12.3ml, 130mmol) was added dropwise and stirred at room 
temperature for 17 hours.  The solution was then concentrated under reduced pressure, co-evaporating 
with toluene and the residue was purified by flash chromatography on silica gel (2:1, Hexanes:EtOAc) to 
yield 3.01 (92:8, α:β) as a white powder (6.22g, 15.85mmol, 95% over two steps).  Spectra were 
consistent with known data.38 
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3.02 2,3,4,6-Tetra-O-acetyl-β-D-glucopyranose  
 
 Hydrazine acetate (1.634g, 17.75mmol) was added to a solution of 3.01 (6.22g, 15.85mmol) in 
DMF (100mL) and allowed to stir for 2 hours under argon.  EtOAc (200mL) was then added followed by 
saturated NaHCO3 to precipitate excess hydrazine acetate and the solids removed by filtering through 
celite.  The organics were then washed with water (2 x 100ml), brine (1 x 100mL), dried with MgSO4 and 
concentrated under reduced pressure to give a slightly yellow syrup (5.52g, 15.85mmol ~100%).  The 
compound was sufficiently pure for use in the synthesis of 3.03.  Spectra was consistent with known 
data.39 
3.03 1-(2,4-dinitrophenoxy)-2,3,4,6-Tetra-O-acetyl-β-D-glucopyranose  
 
DABCO (1.991g, 17.75mmol) and 2,4-dinitrofluorobenzene (2.232mL, 17.75mmol) were added 
to a solution of 3.02 (5.52g, 15.85mmol) in anhydrous DMF (175mL) and allowed to stir overnight under 
argon and in the dark. The solution was concentrated under reduced pressure by co-evaporating with 
toluene. The organics were dissolved in DCM (200mL) and washed with saturated NaHCO3 (1 x 200mL), 
water (2 x 200mL) brine (1 x 200mL), dried over MgSO4, then concentrated under reduced pressure. The 
product was recrystallized from ethanol to yield a white powder (4.17g, 8.11mmol, 51.1%).  Spectra was 
consistent with known data.40 
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3.04 2,4-dinitrophenyl-β-D-glucopyranoside  
 
 A solution of 3.03 (4.17g, 8.12mmol) in anhydrous methanol (200mL) is cooled to 0°C in 
an ice bath.  AcCl (4.91mL, 69.1mmol) was added dropwise to the solution and allowed to stir for 48 
hours at 4°C under argon. Solvents were removed under reduced pressure and the residue was partially 
purified by flash chromatography on silica gel (17:2:1 EtOAc:MeOH:AcOH).  The product was then 
recrystallized from MeOH-Ether-Hexanes to yield a cream colored powder (1.04g, 2.99mmol, 36.8%). 1H 
NMR (500 MHz, CD3OD) δ 3.49-3.93 (m, 6H, H3, H4, H5, H6, H7a, H7b), 5.38-5.40 (d, J = 7.5Hz, 1H, H2), 
7.57-7.58 (d, J = 10Hz, 1H, H10), 8.49-8.51 (d, J = 10Hz, 1H, H10), 8.86 (s, 1H, H8).  Spectra was 
consistent with known data.40 
3.05 (3aR,4R,5S,6S,7R,7aS)-2,2-dimethylhexahydrobenzo[d][1,3]dioxole-4,5,6,7-tetraol 
 
 To a solution of myo-inositol (20.0g, 111 mmol) in DMSO (65mL), 2,2-dimethoxypropane (34mL, 
274.2mmol) and p-toluenesulfonic acid (0.200g, 1.05mmol) were added. The mixture was heated at 
90°C until a clear solution was formed (~30 minutes) and then cooled down to room temperature. 
Ethanol (80mL) and diethyl ether (400mL) were added and allowed to stir for 2 hours. Then, 
triethylamine (4mL) was added and allowed to stir for 4 hours.  The reaction was allowed to sit 
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overnight resulting in a white precipitate. The solids were isolated by vacuum filtration, washed with a 
1:5 solution of methanol-diethyl ether (100mL), and allowed to dry by suction.  The residue was 
dissolved in hot ethanol and solids removed by vacuum filtration. The filtrate was then purified by 
recrystallization from ethanol and solids washed with cold diethyl ether to give a white powder (15.09g, 
68.52mmol, 62%).  1H NMR (500 MHz, D2O) δ 1.37 (s, 3H, CH3), 1.51 (s, 3H, CH3), 3.22-3.25 (t, J = 10Hz, 
1H, H4), 3.54-3.58 (dd, J = 10, 8Hz, 1H, H7) 3.58-3.62 (t, J = 10Hz, 1H, H6), 3.81-3.84 (dd, J = 10, 4Hz, 1H, 
H5), 4.03-4.05 (dd, J = 8, 5Hz, 1H, H7a), 4.45-4.47 (t, J = 5Hz, 1H, H3). 13C NMR (500 MHz, D2O) δ25.04 
(CH3), 27.22(CH3), 69.32 (C7), 72.12(C4), 72.48 (C5), 74.56 (C6), 75.99 (C3), 78.45 (C7a), 110.34 (CH-
(CH3)2).   
3.07 (1R,2R,3S,4R,5R,6S)-3,4,5,6-tetrakis(benzyloxy)cyclohexane-1,2-diol 
 
 A solution of 3.05 (10g, 45.41mmol) in dry DMF (300mL) was cooled to 0°C in an ice bath under 
argon.  NaH (60% in oil, 6.54g, 227.1mmol) was slowly added to the open flask to allow venting of 
hydrogen gas. After stirring for 15 minutes, benzyl bromide (32.58mL, 272.5mmol) was added dropwise 
and the mixture was allowed to stir for 2 days at room temperature under argon.  The reaction was 
quenched by the slow addition of water (50mL) and allowed to stir for 30 minutes allowing hydrogen gas 
to escape. The solution was concentrated under reduced pressure by co-evaporating with toluene for 
the azeotropic removal of DMF.  The residue was dissolved in diethyl ether (100mL), washed with water 
(3 x 100mL), brine (1 x 100mL), dried over Na2SO4, and concentrated under reduced pressure. The 
residue was purified by flash chromatography on silica gel (4:1:1% Hexanes to EtOAc to TEA) to give the 
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clear colorless oil 3.06.  Then, the residue was added to a solution of water (75mL) and glacial acetic acid 
(300mL) and allowed to reflux for 3 hours. Solvents were removed under reduced pressure and the 
residue was purified by flash chromatography on silica gel (2:1, Hexanes:EtOAc) to yield 3.07 as a white 
powder (12.97g, 23.99mmol, 53% over two steps). 1H NMR (500 MHz,CD3OD) δ 3.43-3.46 (t, J = 9.5Hz, 
1H, H1), 3.46-3.49 (dd, J = 9.5,3Hz, 1H, H5), 3.52-3.54 (dd, J = 9.5,3Hz, 1H, H4), 3.80-3.84 (t, J = 9.5Hz, 
1H, H3), 3.93-3.97 (t, J = 9.5Hz, 1H, H6), 4.17-4.18 (t, J = 3Hz, 1H, H2), 4.62-4.93 (m, 8H, CH-CH2-O), 7.23-
7.42 (m, 20H, phenyl). 13C NMR (500 MHz,CD3OD) δ 69.67 (C1), 71.68 (CH2-O), 71.98(CH2-O), 75.03(CH2-
O), 75.21(CH2-O), 80.12 (C5) , 81.30 (C4), 81.77 (C3), 83.13 (C6), 127.06 (CH, phenyl), 127.07 (CH, 
phenyl), 127.10 (CH, phenyl), 127.26 (CH, phenyl), 127.35 (CH, phenyl), 127.59 (CH, phenyl), 127.62 (CH, 
phenyl), 127.65 (CH, phenyl), 127.68 (CH, phenyl), 127.70 (CH, phenyl), 127.75 (CH, phenyl), 127.79 (CH, 
phenyl), 127.81 (CH, phenyl), 127.85 (CH, phenyl), 127.94 (CH, phenyl), 138.48 (C-CH2-O, phenyl), 138.84 
(C-CH2-O, phenyl), 138.88 (C-CH2-O, phenyl), 139.02 (C-CH2-O, phenyl).   
3.08 (1r,2R,3S,4r,5R,6S)-2,3,4,5,6-pentakis(benzyloxy)cyclohexanol 
 
Tetrabutyl ammonium bromide (3.80g, 11.8mmol), dibutyltin oxide (2.90g, 11.6mmol) and benzyl 
bromide (2.00mL, 16.7mmol) are added to a solution of 3.07 (6.00g, 11.1mmol) in acetonitrile and 
allowed to reflux overnight with stirring.  The solution was concentrated under reduced pressure.  The 
residue was dissolved in diethyl ether (100mL), washed with water (3 x 100mL), brine (1 x 100mL), dried 
over Na2SO4, and concentrated under reduced pressure then dissolved in diethyl ether (150mL), washed 
with water (1 x 100mL), dried over Na2SO4, and again concentrated under reduced pressure.  The 
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residue was purified by recrystallization from hot methanol and solids washed with cold methanol to 
give white crystals (5.49g, 8.71mmol, 78%).   
3.09 (1R,2S,3r,4R,5S,6s)-6-azido-1,2,3,4,5-pentabenzyloxycyclohexane 
 
 A solution of 3.08 (1.19g, 1.89mmol) in pyridine (10mL) was cooled to 0°C in an ice bath. 
Methanesulfonyl chloride (1.46mL, 18.9 mmol) was added dropwise and allowed to stir at room 
temperature overnight and under argon. The solution was then concentrated under reduced pressure, 
co-evaporating with toluene.  The residue was dissolved in diethyl ether (100mL) and washed with water 
(1 x 100mL), 1M HCl (1 x 100mL), saturated NaHCO3 (1 x 100mL), brine (1 x 100mL), dried over Na2SO4, 
then concentrated under reduced pressure to yield an orange solid. The thoroughly dried mixture was 
dissolved in DMF (25mL).  NaN3 (1.17g, 17.9mmol) was added and the solution heated to 80°C, stirring 
under argon for 2 days. The reaction was then concentrated under reduced pressure, co-evaporating 
with toluene. The residue was redissolved in EtOAc (50mL), washed with water (1 x 50mL), brine (1 x 
50mL) and dried over Na2SO4, then concentrated under reduced pressure.  The residue was purified by 
flash chromatography on silica gel (11:1 Hexanes:EtOAc) to yield 3.17 as a clear oil (860mg, 1.31mmol, 
69%).  Spectra was consistent with known data. 
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3.10 (1s,2R,3S,4r,5R,6S)-2,3,4,5,6-pentakis(benzyloxy)cyclohexanamine 
 
 A solution of 3.09 (860mg, 1.31mmol) in THF (30mL) was cooled to 0°C in an ice bath. LiAlH4 
(100mg, 2.76mmol) was then slowly added and allowed to stir for 2 hours at 0°C and under argon. 
EtOAc (20mL) was added to the solution to quench the reaction and allowed to stir for an additional 30 
minutes.  The organics were washed with water (1 x 50mL), brine (1 x 50mL), dried over Na2SO4, and 
concentrated under reduced pressure to yield a white solid (810mg, 1.28mmol, 98%). Spectra was 
consistent with known data. 
3.11 (1s,2R,3S,4r,5R,6S)-2,3,4,5,6-pentakis(benzyloxy)-N-hexylcyclohexanamine 
 
Hexanal (45µL, 0.37mmol) was added to a mixture of 3.23 (200mg, 0.318mmol) in 30mL of dry 
methanol.  NaBH3CN (40mg, 0.64mmol) and AcOH (50µL, 0.87mmol) were then added stirring at room 
temperature for four days under argon. To quench the reaction 5mL of water was added and allowed to 
stir for 15 minutes turning the clear solution to a cloudy white mixture. Diethyl ether (3 x 25mL) was 
added to the aqueous solution to extract the organics. The organic portion was dried with brine (1 x 
25mL) and Na2SO4, then concentrated under reduced pressure.  The resulting residue was purified by 
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flash chromatography on silica gel (1:1:3.5% Hexanes: EtOAc:AcOH) to give 3.11 as cream colored solid 
(56mg, 0.079mmol, 25%). 1H NMR (500 MHz, CDCl3) δ 0.82-0.89 (m, 3H, CH3), 1.16-1.38 (m, 8H, CH2), 
2.17 (broad s, 1H, NH), 2.59-2.63 (t, J = 10Hz, 1H, H1), 2.71-2.81 (m, 2H, NH-CH2), 3.40-3.63 (m, 5H, H2, 
H3, H4, H5, H6), 4.72-4.97 (m, 10H, O-CH2), 7.23-7.35 (m, 25H, phenyl).  
13C NMR (500 MHz, CDCl3) δ 
14.21 (CH3), 21.05 (CH2), 22.74 (CH2), 27.30 (CH2), 30.30 (CH2), 31.92 (CH2), 60.41 (C1), 75.55 (C3), 75.79 
(C5), 79.76 (C4), 84.45 (C6), 84.69 (C2), 127.42 (CH, phenyl), 127.56 (CH, phenyl), 127.61 (CH, phenyl), 
127.67 (CH, phenyl), 127.75 (CH, phenyl), 127.79 (CH, phenyl), 127.83 (CH, phenyl), 127.85 (CH, phenyl), 
128.02 (CH, phenyl), 128.26 (CH, phenyl), 128.39 (CH, phenyl), 128.45 (CH, phenyl), 128.52 (CH, phenyl), 
138.25 (C-CH2-O, phenyl), 138.41 (C-CH2-O, phenyl), 138.53 (C-CH2-O, phenyl), 138.61 (C-CH2-O, phenyl), 
138.92 (C-CH2-O, phenyl). 
3.12 (1R,2S,3r,4R,5S,6s)-6-(hexylamino)cyclohexane-1,2,3,4,5-pentaol 
 
 Concentrated HCl (5 drops) was added to a solution of 3.11 (56mg, 0.079mmol) in THF (5mL).  
The system was flushed with argon followed by the addition of 10% Pd/C (50mg, 0.038mmol). The vessel 
was then repeatedly filled and evacuated with hydrogen and the mixture was hydrogenated at 
atmospheric pressure at 70°C for 16 hours with stirring.  The catalyst was removed by vacuum filtration 
through a plug of Celite and was washed with methanol (20mL).  The filtrate was concentrated under 
reduced pressure to provide a yellow oil. The oil was purified by flash chromatography on silica gel 
(4:1:1% Hexanes: EtOAc:TEA). Fractions containing the product were concentrated then lyophilized to 
yield the HCl salt of 3.12 as a white powder (6.0mg, 0.020mmol, 25%). 1H NMR (500 MHz, D2O) δ0.80-
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0.88 (m, 3H, CH3), 1.21-1.40 (m, 6H, CH3), 1.60-1.68 (m, 2H, N-CH2-CH2), 1.85-1.91 (m, 4H, OH), 2.94-
3.07 (m, 3H, N-CH2, H1), 3.26-3.40 (m, 3H, H3, H4, H5), 3.52-3.61 (m, 2H, H2, H6)  
13C NMR (500 MHz, 
CDCl3) δ 13.14 (CH3), 21.68 (CH2), 25.39 (CH2), 26.24 (CH2), 30.38 (CH2), 45.10 (N-CH2), 60.87 (H1), 69.00 
(H2, H6), 72.94 (H4), 74.43 (H3, H5). LRMS (ESI) m/z: 263.1 [M + H]+ Calculated for C12H26NO5
+: 264.1805 
3.13 (1S,2S,3R,4R,5S,6R)-2,3,4,5-tetrakis(benzyloxy)-6-(nonyloxy)cyclohexanol 
 
 Dibutyltin oxide (0.760g, 3.047mmol) was added to a solution of 3.07 (1.500g, 2.77mmol) in 
toluene (25mL). The mixture was refluxed overnight using a Dean-Stark apparatus to remove water as 
the reaction proceeds. The reaction was concentrated under reduced pressure to leave a dark yellow oil 
that foams aggressively before hardening into a thick syrup. The syrup was dissolved in DMF (25mL) 
followed by the addition of Cesium fluoride (0.841g, 5.54mmol) and 1-bromononane (0.582mL, 
3.047mmol) and the mixture allowed to stir under argon for 2 days at room temperature.  The insoluble 
components were removed by vacuum filtration through celite and which was washed with EtOAc.  The 
solution was concentrated under reduced pressure by co-evaporating with toluene.  The residue was 
dissolved in diethyl ether (50mL), washed with water (50mL), brine (50mL), dried over Na2SO4, and 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
(6:1, Hexanes:EtOAc) to yield BA83 as a brown oil (1.47g, 2.204mmol, 79.5%). 1H NMR (500 MHz, CDCl3) 
δ 0.94-0.98 (t, J = 7Hz, 3H, CH3), 1.31-1.51 (m, 12H, CH2), 1.67-1.73 (pentet, J = 7Hz, 2H, O-CH2-CH2), 2.56 
(s, 1H, OH), 3.29-3.32 (dd, J = 9.5, 3.5Hz, 1H, H4), 3.48-3.51 (dd, J = 9.5, 3.5Hz, 1H, H3), 3.51-3.55 (t, J = 
9.5Hz, 1H, H6), 3.61-3.66 (dt, J = 9, 7Hz, 1H, O-CH2), 3.70-3.74 (dt, J = 9, 7Hz, 1H, O-CH2), 3.97-4.01 (t, J = 
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9.5Hz, 1H, H2), 4.06-4.10 (t, J = 9.5Hz, 1H, H5), 4.34-4.35 (t, J = 2.5Hz, 1H, H1), 4.82-4.99 (m, 8H, CH-CH2-
O), 7.28-7.45 (m, 20H, phenyl). 13C NMR (500 MHz, CDCl3) δ 14.21 (CH3), 22.75 (CH2), 26.26 (CH2), 29.36 
(CH2), 29.59 (CH2), 29.62 (CH2), 30.24 (CH2), 31.95 (CH2), 67.35 (C1), 71.17 (CH2-O-C2), 72.81 (C3), 75.96 
(CH2-O-C2), 76.02 (CH2-O-C2), 76.06 (CH2-O-C2), 80.04 (C6), 80.65 (C2), 81.21 (C5), 81.29 (C4), 83.19 
(CH2-CH2-O), 127.60 (CH, phenyl), 127.61 (CH, phenyl), 127.65 (CH, phenyl), 127.90 (CH, phenyl), 127.92 
(CH, phenyl), 128.04 (CH, phenyl), 128.12 (CH, phenyl), 128.39 (CH, phenyl), 128.42 (CH, phenyl), 128.43 
(CH, phenyl), 128.53 (CH, phenyl), 138.10 (C-CH2-O, phenyl), 138.81 (C-CH2-O, phenyl), 138.81 (C-CH2-O, 
phenyl), 138.91 (C-CH2-O, phenyl). 
3.14 (1S,2S,3R,4R,5S,6R)-2,3,4,5-tetrakis(benzyloxy)-6-(hexyloxy)cyclohexanol 
 
Dibutyltin oxide (380mg, 1.53mmol) was added to a solution of 3.07 (750mg, 1.39mmol) in toluene 
(15mL). The mixture was refluxed overnight using a Dean-Stark apparatus to remove water as the 
reaction proceeds. The reaction was concentrated under reduced pressure to leave a dark yellow oil 
that foams aggressively before hardening into a thick syrup. The syrup was dissolved in DMF (10mL) 
followed by the addition of Cesium fluoride (421mg, 2.77mmol) and 1-bromohexane (0.214mL, 
1.53mmol) and the mixture allowed to stir under argon for 2 days at room temperature.  The insoluble 
components were removed by vacuum filtration through celite and which was washed with EtOAc.  The 
solution was concentrated under reduced pressure by co-evaporating with toluene.  The residue was 
dissolved in diethyl ether (50mL), washed with water (50mL), brine (50mL), dried over Na2SO4, and 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
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(5:1, Hexanes:EtOAc) to yield 3.14 as a brown oil (650mg, 1.02mmol, 73.9%). 1H NMR (500 MHz, CDCl3) δ 
0.86-0.89 (t, J = 7Hz, 3H, CH3), 1.24-1.37 (m, 6H, CH2), 1.59-1.64 (quintet, 7Hz, 2H, O-CH2-CH2), 2.47 (s, 
1H, OH), 3.22-3.24 (dd, J = 9, 3Hz, 1H, H6) 3.41-3.43 (dd, J = 9,3Hz, 1H, H2), 3.43-3.47 (t, J = 9Hz, 1H, H3), 
3.54-3.58 (dt, J = 9, 7Hz, 1H, O-CH2), 3.62-3.67  (dt, J = 9, 7Hz, 1H, O-CH2), 3.89-3.93 (t, J = 9Hz, 1H, H5), 
3.98-4.02 (t, J = 9Hz, 1H, H4), 4.26-4.27 (t, J = 3Hz, 1H, H1), 4.74-4.91 (m, 8H, CH-CH2-O), 7.24-7.38 (m, 
20H, phenyl). 13C NMR (500 MHz, CDCl3) δ 14.13 (CH3), 22.65 (CH2), 25.90 (CH2), 30.18 (CH2), 31.75 (CH2), 
67.32 (C1), 71.17(CH2-O-C2), 72.81 (C3), 75.96 (CH-CH2-O), 76.01 (CH-CH2-O), 76.06 (CH-CH2-O), 80.00 
(C6), 80.60 (C2), 81.16 (C5), 81.26 (C4), 83.15 (CH2-CH2-O), 127.60 (CH, phenyl), 127.61 (CH, phenyl), 
127.65 (CH, phenyl), 127.91 (CH, phenyl), 128.04 (CH, phenyl), 128.11 (CH, phenyl), 128.38 (CH, phenyl), 
128.41 (CH, phenyl), 128.52 (CH, phenyl), 138.05 (C-CH2-O, phenyl), 138.76 (C-CH2-O, phenyl), 138.85 (C-
CH2-O, phenyl).  
3.16 ((((1S,2R,3R,4S,5R,6R)-5-azido-6-(nonyloxy)cyclohexane-1,2,3,4-
tetrayl)tetrakis(oxy))tetrakis(methylene))tetrabenzene 
 
 A solution of BA83 (1.39g, 2.084mmol) in pyridine (5mL) was cooled to 0°C in an ice bath. 
Methanesulfonyl chloride (0.81 mL, 10.42mmol) was added dropwise and allowed to stir at room 
temperature overnight and under argon. The solution was then concentrated under reduced pressure, 
co-evaporating with toluene.  The residue was dissolved in diethyl ether (100mL) and washed with water 
(2 x 100mL), 1M HCl (1 x 100mL), saturated NaHCO3 (1 x 100mL), brine (1 x 100mL), dried over Na2SO4, 
then concentrated under reduced pressure to yield a golden yellow syrup (1.40g). The thoroughly dried 
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mixture was dissolved in DMF (20mL).  NaN3 (1.29g, 19.80mmol) was added and allowed to stir at room 
temperature and under argon for 2 days. The reaction was then concentrated under reduced pressure, 
co-evaporating with toluene. The residue was redissolved in EtOAc (50mL), washed with water (1 x 
50mL), brine (1 x 50mL) and dried over Na2SO4, then concentrated under reduced pressure.  The residue 
was purified by flash chromatography on silica gel (25:1 Hexanes:EtOAc) to yield BA85 as a clear, faintly 
yellow oil (0.92g, 1.330mmol, 64%). 1H NMR (500 MHz, CDCl3) δ 0.86-0.89 (t, J = 7Hz, 3H, CH3), 1.25-1.35 
(m, 12H, CH2), 1.61-1.65 (sextet,  J = 7Hz, 2H, O-CH2-CH2-CH2), 3.12-3.16 (t, J = 10Hz, 1H, H2), 3.27-3.30 
(t, J = 10Hz, 1H, H3), 3.38-3.54 (m, 4H, H1, H4, H5, H6) 3.74-3.76 (q, J = 7Hz, 1H, O-CH2-CH2), 3.81-3.83 
76 (q, J = 7Hz, 1H, O-CH2-CH2),  4.83-4.88 (m, 8H, CH-CH2-O), 7.24-7.34 (m, 20H, phenyl). 
13C NMR (500 
MHz, CDCl3) δ 14.18 (CH3), 22.72 (CH2), 26.15 (CH2), 29.32 (CH2), 29.59 (CH2), 30.38 (CH2), 31.92 (CH2), 
66.93(C5), 74.27(O-CH2-CH2), 75.99-76.05 (O-CH2-CH), 81.01(C3), 81.42 (C1), 82.52 (C2), 83.27 (C4), 
83.31 (C6), 127.78 (CH, phenyl), 127.85 (CH, phenyl), 127.90 (CH, phenyl), 127.97 (CH, phenyl), 128.27 
(CH, phenyl), 128.48 (CH, phenyl), 137.86 (C-CH2-O, phenyl), 138.31 (C-CH2-O, phenyl).  
3.17  ((((1S,2R,3R,4S,5R,6R)-5-azido-6-(hexyloxy)cyclohexane-1,2,3,4-
tetrayl)tetrakis(oxy))tetrakis(methylene))tetrabenzene 
 
A solution of 3.14 (650mg, 1.03mmol) in pyridine (10mL) was cooled to 0°C in an ice bath. 
Methanesulfonyl chloride (0.397mL, 5.13mmol) was added dropwise and allowed to stir at room 
temperature overnight and under argon. The solution was then concentrated under reduced pressure, 
co-evaporating with toluene.  The residue was dissolved in diethyl ether (100mL) and washed with water 
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(2 x 100mL), 1M HCl (1 x 100mL), saturated NaHCO3 (1 x 100mL), brine (1 x 100mL), dried over Na2SO4, 
then concentrated under reduced pressure to yield a golden yellow syrup. The thoroughly dried mixture 
was dissolved in DMF (20mL).  NaN3 (600mg, 9.23mmol) was added and allowed to stir at room 
temperature and under argon for 2 days. The reaction was then concentrated under reduced pressure, 
co-evaporating with toluene. The residue was redissolved in EtOAc (50mL), washed with water (1 x 
50mL), brine (1 x 50mL) and dried over Na2SO4, then concentrated under reduced pressure.  The residue 
was purified by flash chromatography on silica gel (25:1 Hexanes:EtOAc) to yield 3.17 as a clear, faintly 
yellow oil (354mg, 0.5448mmol, 53%).1H NMR (500 MHz, CDCl3) δ 0.86-0.88 (t, J = 7Hz, 3H, CH3), 1.24-
1.38 (m, , 6H, CH2), 1.58-1.68 (octet, J = 7Hz, 2H, O-CH2-CH2), 3.12-3.16 (t, J = 9Hz, 1H, H5), 3.27-3.30 (t, J 
= 9Hz, 1H, H1), 3.37-3.41 (t, J = 9Hz, 1H, H2), 3.44-3.50(m, 2H, H3, H4), 3.51-3.56 (q, J = 9Hz, 1H, H6), 
3.73-3.78 (dt, J = 9, 7Hz, 1H, O-CH2), 3.81-3.85 (dt, J = 9, 7Hz, 1H, O-CH2), 4.81-4.88 (m, 8H, CH-CH2-O), 
7.19-7.36 (m, 20H, phenyl). 13C NMR (500 MHz, CDCl3) δ 14.14 (CH3), 22.70 (CH2), 25.86 (CH2), 30.39 
(CH2), 31.81 (CH2), 67.03 (C5), 74.28 (O-CH2-CH), 75.98 (O-CH2-CH), 76.01 (O-CH2-CH), 76.01 (O-CH2-CH), 
76.07 (O-CH2-CH), 81.09 (C3), 81.50(C1), 82.60 (C2), 83.34 (C4), 83.38 (C6), 127.77 (CH, phenyl), 127.79 
(CH, phenyl), 127.81 (CH, phenyl), 127.87 (CH, phenyl), 127.88 (CH, phenyl), 127.90 (CH, phenyl), 127.91 
(CH, phenyl), 127.93 (CH, phenyl), 127.94 (CH, phenyl), 127.99 (CH, phenyl), 128.29 (CH, phenyl), 128.48 
(CH, phenyl), 128.49 (CH, phenyl), 128.51 (CH, phenyl), 128.51 (CH, phenyl), 128.52 (CH, phenyl), 128.55 
(CH, phenyl), 128.56 (CH, phenyl), 137.96 (C-CH2-O, phenyl), 138.39 (C-CH2-O, phenyl), 138.40 (C-CH2-O, 
phenyl), 138.42 (C-CH2-O, phenyl). 
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3.19 (1R,2S,3R,4S,5S,6R)-5-amino-6-(nonyloxy)cyclohexane-1,2,3,4-tetraol 
 
In a high pressure reaction vessel, concentrated HCl (5 drops) was added to a solution of 3.16 
(150mg, 0.225mmol) in methanol (10mL).  The system was flushed with argon followed by the addition 
of 10% Pd/C (120mg, 0.113mmol). The vessel was then repeatedly filled and evacuated with hydrogen 
and the mixture was hydrogenated at 50 psi for 16 hours with stirring.  The catalyst was removed by 
vacuum filtration through a plug of Celite and was washed with methanol (20mL).  The filtrate was 
concentrated under reduced pressure to provide a white powder. The residue was dissolved in water 
(2mL), basified with concentrated NH4OH (1mL) to yield a black precipitate and the solution was purified 
by reversed phase chromatography (Thermo Scientific, Hypersep C18, 2000mg, 15mL ) using a gradient 
of water to methanol (0% to 100% MeOH at 20% increments). Fractions containing the product were 
concentrated then lyophilized to yield the HCl salt of 3.19 as a white powder (54mg, 0.16mmol, 70%). 1H 
NMR (500 MHz, CD3OD) δ0.88-0.91 (t, J = 7Hz, 3H, CH3), 1.24-1.37 (m, 12H, CH2), 1.57-1.65 (octet, J = 
7Hz, 2H, O-CH2-CH2), 2.60-2.64 (t, J = 9Hz, 1H, H5), 2.93-2.97 (t, J = 9Hz, 1H, H6), 3.10-3.20 (m, 3H, H2, 
H3, H4), 3.30-3.35 (m, 1H, H1), 3.57-3.62 (dt, J = 9, 7Hz, 1H, O-CH2), 3.94-3.99 (dt, J = 9, 7Hz, 1H, O-CH2). 
13C NMR (500 MHz, CD3OD) δ 13.06 (CH3), 22.35 (CH2), 25.85 (CH2), 29.05 (CH2), 29.30 (CH2), 29.34 (CH2), 
30.03 (CH2), 31.67 (CH2), 55.23 (C5), 72.85 (O-CH2), 73.72 (C1), 74.57 (C4), 75.27 (C2), 75.67 (C3), 82.52 
(C6). LRMS (ESI) m/z: 292.2 [M + H]+ Calculated for C14H30NO5
+: 292.2118 
83 
 
3.20 (1R,2S,3R,4S,5S,6R)-5-amino-6-(hexyloxy)cyclohexane-1,2,3,4-tetraol 
 
In a high pressure reaction vessel, concentrated HCl (5 drops) was added to a solution of 3.17 
(354mg, 0.545mmol) in methanol (15mL).  The system was flushed with argon followed by the addition 
of 10% Pd/C (290mg, 0.272mmol). The vessel was then repeatedly filled and evacuated with hydrogen 
and the mixture was hydrogenated at 50 psi for 16 hours with stirring.  The catalyst was removed by 
vacuum filtration through a plug of Celite and was washed with methanol (20mL).  The filtrate was 
concentrated under reduced pressure to provide a white powder. The residue was dissolved in water 
(2mL), basified with concentrated NH4OH (1mL) to yield a black precipitate and the solution was purified 
by reversed phase chromatography (Thermo Scientific, Hypersep C18, 2000mg, 15mL ) using a gradient 
of water to methanol (0% to 100% MeOH at 20% increments). Fractions containing the product were 
concentrated then lyophilized to yield the HCl salt of 3.20 as a white powder (47mg, 0.16mmol, 29%). 1H 
NMR (500 MHz, CD3OD) δ 0.80-0.82 (t, J = 7Hz, 3H, CH3), 1.23-1.28 (m, 6H, CH2), 1.53-1.57 (pentet, J = 
7Hz, 2H, O-CH2-CH2), 2.78-2.82 (t, J = 10hz, 1H, H5), 3.10-3.32 (m, 5H, H1, H2, H3, H4, H6), 3.53-3.57 (q, J 
= 7Hz, 1H, O-CH2), 3.89-3.93 (q, J = 7Hz, 1H, O-CH2). 
13C NMR (500 MHz, CD3OD) δ 13.06 (CH3), 22.33 
(CH2), 25.33 (CH2), 29.69 (CH2), 31.57 (CH2), 55.48 (C5), 70.14 (O-CH2), 73.02 (C1), 74.18 (C4), 74.86 (C2), 
75.73 (C3), 78.07 (C6). LRMS (ESI) m/z: 264.2 [M + H]+ Calculated for C12H26NO5
+: 236.1492 
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3.21(1R,2S,3R,4S,5S,6R)-5-amino-6-butoxycyclohexane-1,2,3,4-tetraol 
 
In a high pressure reaction vessel, concentrated HCl (4 drops) was added to a solution of 3.18 (95mg, 
0.545mmol) in methanol (10mL).  The system was flushed with argon followed by the addition of 10% 
Pd/C (85mg, 0.080mmol). The vessel was then repeatedly filled and evacuated with hydrogen and the 
mixture was hydrogenated at 50 psi for 16 hours with stirring.  The catalyst was removed by vacuum 
filtration through a plug of Celite and was washed with methanol (20mL).  The filtrate was concentrated 
under reduced pressure to provide a white powder. The residue was dissolved in water (2mL), basified 
with concentrated NH4OH (1mL) to yield a black precipitate and the solution was purified by reversed 
phase chromatography (Thermo Scientific, Hypersep C18, 2000mg, 15mL ) using a gradient of water to 
methanol (0% to 100% MeOH at 20% increments). Fractions containing the product were concentrated 
then lyophilized to yield the HCl salt of 3.20 as a slightly brown powder (12mg, 0.045mmol, 28%). 1H 
NMR (500 MHz, CD3OD) δ0.89-0.92 (t, J = 7Hz, 3H, CH3), 1.32-1.38 (Hextet, J = 7Hz, 2H, CH2-CH3), 1.57-
1.64 (Hextet, J = 7Hz, 2H, O-CH2-CH2), 2.84-2.89 (t, J = 10Hz, 1H, H5), 3.16-3.39 (m, 5H, H1, H2, H3, H4, 
H6) 3.59-3.64 (q, J = 7Hz, 1H, O-CH2), 3.96-4.00 (q, J = 7Hz, 1H, O-CH2).   
13C NMR (500 MHz, CD3OD) 
δ13.00 (CH3), 18.78 (CH2), 31.84 (CH2), 55.49 (C5), 70.13 (O-CH2), 72.69 (C1), 74.17 (C4), 74.85 (C2), 75.73 
(C3), 78.04 (C6). LRMS (ESI) m/z: 236.1 [M + H]+ Calculated for C10H22NO5
+: 236.1492 
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3.22 (1R,2S,3R,4R,5S,6R)-2,3,4,5-tetrakis(benzyloxy)-6-(nonyloxy)cyclohexanamine 
 
 A solution of BA107 (1.43g, 2.07mmol) in THF (30mL) was cooled to 0°C in an ice bath. LiAlH4 
(165mg, 4.34mmol) was then slowly added and allowed to stir for 2.5 hours at 0°C and under argon. 
EtOAc (20mL) was added to the solution to quench the reaction and allowed to stir for an additional 30 
minutes.  The organics were washed with water (1 x 50mL), brine (1 x 50mL), dried over Na2SO4, and 
concentrated under reduced pressure to yield a white solid (1.38g, 2.07mmol, 100%). 1H NMR (500 MHz, 
CDCl3) δ 0.90-0.95 (t, J = 7Hz, 3H, CH3), 1.30-1.41 (m, 12H, CH2), 1.59-1.69 (octet,  J = 7Hz, 2H, O-CH2-CH2-
CH2), 1.92-1.96 (broad s, 2H, NH2), 2.92-2.96 (t, J = 10Hz, 1H, H1), 3.17-3.21 (t, J = 9Hz, 1H, H2), 3.36-
3.40 (t, J = 9Hz, 1H, H6), 3.56-3.72 (m, 4H, H3, H4, H5, O-CH2-CH2), 3.96-4.01 (dq, J = 10, 6Hz, 1H, O-CH2-
CH2), 4.74-5.06 (m,  8H, O-CH2-C, phenyl), 7.30-7.41 (m, 20H, phenyl). 
13C NMR (500 MHz, CDCl3) δ 14.17 
(CH3), 22.72 (CH2), 26.22 (CH2), 29.30 (CH2), 29.57 (CH2), 29.60 (CH2), 30.57 (CH2), 31.90 (CH2), 55.46 (C1), 
74.05 (C3), 75.77 (O-CH2-C), 75.81 (O-CH2-C), 75.88 (O-CH2-C), 76.05 (O-CH2-C), 82.75 (C5), 83.16 (C4), 
83.54 (C2), 84.36 (C6), 127.68 (CH, phenyl), 127.71 (CH, phenyl), 127.73 (CH, phenyl), 127.86 (CH, 
phenyl), 127.88 (CH, phenyl), 127.93 (CH, phenyl), 128.46 (CH, phenyl), 128.50 (CH, phenyl), 128.59 (CH, 
phenyl), 138.44 (C-CH2-O, phenyl), 138.44 (C-CH2-O, phenyl), 138.51 (C-CH2-O, phenyl).  
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3.23 (1R,2S,3R,4R,5S,6R)-2,3,4,5-tetrakis(benzyloxy)-6-(hexyloxy)cyclohexanamine 
 
A solution of BA191 (3.17) (1.10g, 1.69mmol) in THF (30mL) was cooled to 0°C in an ice bath. 
LiAlH4 (135mg, 3.56mmol) was then slowly added and allowed to stir for 2.5 hours at 0°C and under 
argon. EtOAc (20mL) was added to the solution to quench the reaction and allowed to stir for an 
additional 30 minutes.  The organics were washed with water (1 x 50mL), brine (1 x 50mL), dried over 
Na2SO4, and concentrated under reduced pressure to yield a white solid (1.03g, 1.65mmol, 98%). 
1H 
NMR (500 MHz, CDCl3) δ 0.84-0.87 (t, J = 7Hz, 3H, CH3), 1.22-1.34 (m, 6H, CH2), 1.51-1.64 (octet,  J = 7Hz, 
2H, O-CH2-CH2-CH2), 1.85 (broad s, 2H, NH2), 2.87-2.91 (t, J = 10Hz, 1H, H1), 3.12-3.15 (t, J = 9Hz, 1H, 
H2), 3.30-3.34 (t, J = 9Hz, 1H, H6), 3.37-3.67 (m, 4H, H3, H4, H5, O-CH2-CH2), 3.91-3.96 (q, J = 7Hz, 1H, O-
CH2-CH2), 4.61-5.00 (m,  8H, O-CH2-C, phenyl), 7.19-7.34 (m, 20H, phenyl). 
13C NMR (500 MHz, CDCl3) δ 
14.13 (CH3), 22.68 (CH2), 25.90 (CH2), 30.55 (CH2), 31.78 (CH2), 55.51 (C1), 74.05 (C3), 75.82-76.05 (O-
CH2-C), 82.82 (C5), 83.21 (C4), 83.58 (C2), 84.39 (C6), 127.68 (CH, phenyl), 127.71 (CH, phenyl), 127.73 
(CH, phenyl), 127.85 (CH, phenyl), 127.87 (CH, phenyl), 127.93 (CH, phenyl), 127.94 (CH, phenyl), 127.96 
(CH, phenyl), 127.98 (CH, phenyl), 128.42 (CH, phenyl), 128.42 (CH, phenyl), 128.44 (CH, phenyl), 128.46 
(CH, phenyl), 128.49 (CH, phenyl), 128.58 (CH, phenyl), 138.43 (C-CH2-O, phenyl), 138.44 (C-CH2-O, 
phenyl), 138.51 (C-CH2-O, phenyl). 
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3.24 (1R,2S,3R,4R,5S,6R)-2,3,4,5-tetrakis(benzyloxy)-6-(nonyloxy)-N-octylcyclohexanamine 
 
 Octanal (42.21µL, 0.270mmol) was added to a solution of 3.22 (120mg, 0.180mmol) in 5mL of 
dry methanol and was stirred at room temperature overnight and under argon. NaBH4 (13.6mg, 
0.360mmol) was then carefully added and allowed to stir for 30 minutes.  To quench the reaction 5mL of 
a 1M NaOH solution was added and allowed to stir for another 15 minutes. Diethyl ether (25mL) was 
added to the aqueous solution to extract the organics, and then washed once with water (25mL). The 
organic portion was dried with brine (25mL) and Na2SO4, then concentrated under reduced pressure.  
The resulting residue was purified by flash chromatography on silica gel (10:1 Hexanes: EtOAc) to give 
3.24 as cream colored solid (94mg, 0.121mmol, 67%). 1H NMR (500 MHz, CDCl3) δ 0.83 (t, J = 7Hz, 6H, 
CH3),  1.19-1.36 (m, 24H, CH2), 1.38-1.44 (m, 2H, N-CH2-CH2), 1.53-1.63 (m, 2H, O-CH2-CH2), 1.78 (broad 
s, 1H, NH),  2.53-2.57 (t, J = 10Hz, 1H, H1), 2.73-2.83 (qt, J = 11, 7Hz, 2H, N-CH2), 3.15-3.18 (dt, J = 10, 
8Hz, 1H, H2),  3.34-3.38 (t, J = 10Hz, 1H, H6), 3.50-3.53 (dd, J = 7, 3Hz, 1H, H4,), 3.54-3.65 (m, 3H, H3, H5, 
O-CH2), 3.89-3.94 (q, J = 8Hz, 1H, O-CH2), 4.72-4.96 (m, 8H, CH-CH2-O), 7.24-7.34 (m, 20H, phenyl). 
13C 
NMR (500 MHz, CDCl3) δ 14.16 (CH3), 22.72 (CH2), 26.31 (CH2), 27.39 (CH2), 29.34 (CH2), 29.63 (CH2), 
30.61 (CH2), 30.86 (CH2), 31.91 (CH2), 50.37 (CH2-NH), 62.20 (C1), 73.93 (C3), 75.62 (O-CH2-Phenyl), 75.82 
(O-CH2-Phenyl), 75.86 (O-CH2-Phenyl), 75.97 (O-CH2-Phenyl),  82.41 (C5), 82.80 (C4), 83.24 (C2), 84.40 
(C6), 127.68 (CH, phenyl), 127.86 (CH, phenyl), 127.97 (CH, phenyl), 128.45 (CH, phenyl), 128.52 (CH, 
phenyl), 138.52 (C-CH2-O). 
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3.25 (1R,2S,3R,4R,5S,6R)-2,3,4,5-tetrakis(benzyloxy)-N-hexyl-6-(nonyloxy)cyclohexanamine 
 
Hexanal (33µL, 0.27mmol) was added to a solution of B109 (120mg, 0.180mmol) in 5mL of dry methanol 
and was stirred at room temperature overnight and under argon. NaBH4 (14mg, 0.37mmol) was then 
carefully added and allowed to stir for 30 minutes.  To quench the reaction 5mL of a 1M NaOH solution 
was added and allowed to stir for another 15 minutes. Diethyl ether (25mL) was added to the aqueous 
solution to extract the organics, and then washed once with water (25mL). The organic portion was 
dried with brine (25mL) and Na2SO4, and then concentrated under reduced pressure.  The resulting 
residue was purified by flash chromatography on silica gel (10:1 hexanes: EtOAc) to give 3.28 as cream 
colored solid (59mg, 0.079mmol, 44%). 1H NMR (500 MHz, CDCl3) δ 0.83-0.92 (dt, J = 7, 3Hz, 6H, CH3), 
1.20-1.37 (m, 18H, CH2), 1.40-1.46 (pentet, J = 7Hz, 2H, NH-CH2-CH2), 1.54-1.64 (hextet, J = 7Hz, 2H, O-
CH2-CH2),  1.97 (broad s, 1H, NH), 2.53-2.57 (t, J = 10Hz, 1H, H1), 2.74-2.83 (qt, J = 11, 7Hz, 2H, N-CH2), 
3.15-3.19 (dt, J = 10, 8Hz, 1H, H2), 3.34-3.38 (t, J = 10Hz, 1H, H6), 3.50-3.65 (m, 4H, H3, H4, H5, O-CH2-
CH2), 3.89-3.94 (dq, J = 7, 6Hz, 1H, O-CH2), 4.72-4.96 (m, 8H, CH-CH2-O), 7.23-7.35 (m, 20H, phenyl). 
13C 
NMR (500 MHz, CDCl3) δ 14.12 (CH3), 14.16 (CH3), 22.68 (CH2), 26.30 (CH2), 27.06 (CH2), 29.32 (CH2), 
29.62 (CH2), 30.61 (CH2), 30.81 (CH2), 31.85 (CH2), 31.91 (CH2), 50.38 (N-CH2), 62.21(C1), 73.94 (C3), 
75.62 (O-CH2-Phenyl), 75.82 (O-CH2-Phenyl), 75.86 (O-CH2-Phenyl), 75.98 (O-CH2-Phenyl), 82.39 (C5), 
82.79 (C4), 83.24 (C2), 84.40 (C6), 127.68 (CH, phenyl), 127.86 (CH, phenyl), 127.98 (CH, phenyl), 128.45 
(CH, phenyl), 128.52 (CH, phenyl), 138.35 (C-CH2-O), 138.46 (C-CH2-O), 138.51 (C-CH2-O) 
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3.26 (1R,2S,3R,4R,5S,6R)-2,3,4,5-tetrakis(benzyloxy)-N-butyl-6-(nonyloxy)cyclohexanamine 
 
Butyraldehyde (33µL, 0.37mmol) was added to a solution of B109 (120mg, 0.180mmol) in 5mL 
of dry methanol and was stirred at room temperature overnight and under argon. NaBH4 (17mg, 
0.45mmol) was then carefully added and allowed to stir for 30 minutes.  To quench the reaction 5mL of 
a 1M NaOH solution was added and allowed to stir for another 15 minutes. Diethyl ether (25mL) was 
added to the aqueous solution to extract the organics, and then washed once with water (25mL). The 
organic portion was dried with brine (25mL) and Na2SO4, and then concentrated under reduced 
pressure.  The resulting residue was purified by flash chromatography on silica gel (10:1 hexanes: EtOAc) 
to give 3.28 as cream colored solid (92mg, 0.13mmol, 71%). 1H NMR (500 MHz, CDCl3) δ 0.87-0.90 (dt, J 
= 7, 2Hz, 6H, CH3), 1.25-1.35 (m, 14H, CH2), 1.39-1.45 (pentet, J = 7Hz, 2H, N-CH2-CH2), 1.56-1.63 (hextet, 
J = 7Hz, 2H, O-CH2-CH2) , 1.99 (broad s, 1H, NH), 2.53-2.57 (t, J = 10Hz, 1H, H1), 2.75-2.85  (qt, J = 11, 
7Hz, 2H, N-CH2), 3.16-3.19 (dt, J = 10, 8Hz, 1H, H2), 3.35-3.39 (t, J = 10Hz, 1H, H6), 3.51-3.66 (m, 4H, H3, 
H4, H5, O-CH2-CH2), 3.90-3.95 (dq, J = 7, 6Hz, 1H, O-CH2), 4.73-4.97 (m, 8H, CH-CH2-O), 7.25-7.35 (m, 
20H, phenyl). 13C NMR (500 MHz, CDCl3) δ 14.08 (CH3), 14.17 (CH3), 20.47 (CH2), 22.71 (CH2), 26.30 (CH2), 
29.31 (CH2), 29.61 (CH2), 30.60 (CH2), 31.91 (CH2), 32.98 (CH2), 50.05 (N-CH2), 62.22 (C1), 73.94 (C3), 
75.65 (O-CH2-Phenyl), 75.83 (O-CH2-Phenyl), 75.87 (O-CH2-Phenyl), 75.98 (O-CH2-Phenyl), 82.43 (C5), 
82.82 (C4), 83.25 (C2), 84.41 (C6), 127.69 (CH, phenyl), 127.86 (CH, phenyl), 128.00 (CH, phenyl), 128.46 
(CH, phenyl), 128.53 (CH, phenyl), 138.47 (C-CH2-O), 138.52 (C-CH2-O). LRMS (ESI) m/z: 362.3 [M + H]
+ 
Calculated for C19H40NO5
+: 362.2901 
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3.27 (1R,2S,3R,4R,5S,6R)-2,3,4,5-tetrakis(benzyloxy)-6-(hexyloxy)-N-octylcyclohexanamine 
 
Octanal (100µL, 0.640 mmol) was added to a solution of 3.23 (200mg, 0.321mmol) in 8mL of dry 
methanol and was stirred at room temperature overnight and under argon. NaBH4 (30.3mg, 0.801mmol) 
was then carefully added and allowed to stir for 30 minutes.  To quench the reaction 5mL of a 1M NaOH 
solution was added and allowed to stir for another 15 minutes. Diethyl ether (25mL) was added to the 
aqueous solution to extract the organics, and then washed once with water (25mL). The organic portion 
was dried with brine (25mL) and Na2SO4, and then concentrated under reduced pressure.  The resulting 
residue was purified by flash chromatography on silica gel (6:1 hexanes: EtOAc) to give 3.28 as white 
solid (125mg, 0.170mmol, 53%). 1H NMR (500 MHz, CDCl3) δ 0.82-0.89 (m, 6H, CH3), 1.14-1.36 (m, 16H, 
CH2), 1.40-1.44 (pentet, J = 7Hz, 2H, NH2-CH2-CH2), 1.52-1.63 (m, 2H, O-CH2-CH2), 1.72 (broad s, 2H, NH2), 
2.53-2.57 (t, J = 10Hz, 1H, H1), 2.74-2.83 (qt, J = 11, 7Hz, 2H, NH-CH2), 3.15-3.19 (tt, J = 10, 7Hz, 1H, H2), 
3.34-3.38 (t, J = 10Hz, 1H, H6), 3.50-3.66 (m, 4H, H3, H4, H5, O-CH2-CH2), 3.89-3.94 (dq, J = 7, 6Hz, 1H, O-
CH2), 4.72-4.96 (m, 8H, CH-CH2-O), 7.23-7.33  (m, 20H, phenyl).
 13C NMR (500 MHz, CDCl3) δ 14.07 (CH3), 
14.15 (CH3), 22.66 (CH2), 22.70 (CH2), 22.72 (CH2), 25.84 (CH2), 25.96 (CH2), 27.40 (CH2), 29.34 (CH2), 
29.47 (CH2), 29.62 (CH2), 30.58 (CH2), 30.88 (CH2), 31.82 (CH2), 31.87 (CH2), 31.90 (CH2), 32.89 (CH2), 
50.35 (N-CH2), 62.24 (C1), 62.94 (C3), 73.92 (O-CH2-CH2), 75.59 (O-CH2-Phenyl), 75.79 (O-CH2-Phenyl), 
75.84 (O-CH2-Phenyl), 75.95 (O-CH2-Phenyl), 82.47(C5) , 82.83 (C4), 83.28 (C2), 84.43 (C6), 127.65 (CH, 
phenyl), 127.66 (CH, phenyl), 127.78 (CH, phenyl), 127.80 (CH, phenyl), 127.80 (CH, phenyl), 127.81 (CH, 
phenyl), 127.82 (CH, phenyl), 127.84 (CH, phenyl), 127.86 (CH, phenyl), 127.88 (CH, phenyl), 127.88 (CH, 
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phenyl), 127.95 (CH, phenyl), 127.97 (CH, phenyl), 128.43 (CH, phenyl), 128.44 (CH, phenyl), 128.45 (CH, 
phenyl), 128.51 (CH, phenyl), 128.53 (CH, phenyl), 138.43 (C-CH2-O), 138.52 (C-CH2-O), 138.56 (C-CH2-O), 
138.59 (C-CH2-O). 
3.28 (1R,2S,3R,4R,5S,6R)-2,3,4,5-tetrakis(benzyloxy)-N-butyl-6-(hexyloxy)cyclohexanamine 
 
 Butyraldehyde (100µL, 1.13mmol) was added to a solution of 3.23 (200mg, 0.321mmol) in 8mL 
of dry methanol and was stirred at room temperature overnight and under argon. NaBH4 (48.5mg, 
1.28mmol) was then carefully added and allowed to stir for 30 minutes.  To quench the reaction 5mL of 
a 1M NaOH solution was added and allowed to stir for another 15 minutes. Diethyl ether (25mL) was 
added to the aqueous solution to extract the organics, and then washed once with water (25mL). The 
organic portion was dried with brine (25mL) and Na2SO4, and then concentrated under reduced 
pressure.  The resulting residue was purified by flash chromatography on silica gel (6:1 hexanes: EtOAc) 
to give 3.28 as cream colored solid (82mg, 0.121mmol, 38%). 1H NMR (500 MHz, CDCl3) δ 0.85-0.94 (m, 
6H, CH3), 1.21-1.37 (m, 8H, CH2), 1.39-1.45 (pentet, J = 7Hz, 2H, N-CH2-CH2), 1.54-1.61 (m, 2H, O-CH2-
CH2), 1.78 (broad s, 1H, NH), 2.53-2.57 (t, J = 10Hz, 1H, H1), 2.75-2.84 (m, 2H, N-CH2), 3.15-3.17 (t, J = 
8Hz, 1H, H2), 3.34-3.37 (t, J = 9Hz, 1H, H6), 3.51-3.66 (m, 4H, H3, H4, H5, O-CH2-CH2), 3.89-3.94 (q, J = 
8Hz, 1H, O-CH2), 4.72-4.98 (m, 8H, CH-CH2-O), 7.19-7.34 (m, 20H, phenyl).
 13C NMR (500 MHz, CDCl3) δ 
14.14 (CH3), 20.54 (CH2), 22.73 (CH2), 26.03 (CH2), 30.64 (CH2), 31.89 (CH2), 33.08 (CH2), 50.11 (CH2-NH), 
62.34 (C1), 74.01 (C3), 75.70 (O-CH2-Phenyl), 75.88 (O-CH2-Phenyl), 75.93 (O-CH2-Phenyl), 76.04 (O-CH2-
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Phenyl), 82.56 (C5), 82.94 (C4), 83.37 (C2), 84.50 (C6), 127.75 (CH, phenyl), 127.88 (CH, phenyl), 127.93 
(CH, phenyl), 128.06 (CH, phenyl), 128.52 (CH, phenyl), 128.60 (CH, phenyl), 138.50 (C-CH2-O, phenyl), 
138.59 (C-CH2-O, phenyl), 138.64 (C-CH2-O, phenyl).  
3.29 (1S,2R,3S,4R,5R,6S)-5-(nonyloxy)-6-(octylamino)cyclohexane-1,2,3,4-tetraol 
 
 In a high pressure reaction vessel, concentrated HCl (4 drops) was added to a solution of 3.24 
(50mg, 0.064mmol) in methanol (4mL).  The system was flushed with argon followed by the addition of 
10% Pd/C (50mg, 0.038mmol). The vessel was then repeatedly filled and evacuated with hydrogen and 
the mixture was hydrogenated at 50 psi for 16 hours with stirring.  The catalyst was removed by vacuum 
filtration through a plug of Celite and was washed with methanol (20mL).  The filtrate was concentrated 
under reduced pressure to provide dark orange crystals. The crystals were dissolved in water (2mL), 
basified with concentrated NH4OH (1mL) to yield a black precipitate and the solution was purified by 
reversed phase chromatography (Thermo Scientific, Hypersep C18, 2000mg, 15mL ) using a gradient of 
water to methanol (0% to 100% MeOH at 20% increments). Fractions containing the product were 
concentrated then lyophilized to yield the HCl salt of 3.29 as a pure white powder (16.82mg, 35.6 mmol, 
56%). 1H NMR (500 MHz, CD3OD) δ 0.91-0.90 (d, J = 5Hz, 6H, CH3), 1.31 (m, 22H, CH2-CH3), 1.63 (m, 1H, 
N-CH2-CH2-CH2), 1.75 (m, 1H, O-CH2-CH2-CH2), 3.01-3.03 (m, 1H, N-CH2), 3.12 (m, 1H, H6), δ3.21-3.28 (m, 
3H, H2, H3, H5), δ3.42-3.44 (m, 1H, N-CH2), δ3.52-3.54 (m, 2H, H1, H4), 3.66 (m, 1H, O-CH2), 4.16 (m, 1H, 
O-CH2).  
13C NMR (500 MHz, CD3OD) δ 13.11(CH3), 22.37 (CH2), 22.39 (CH2), 25.94 (CH2), 26.00 (CH2), 
26.39 (CH2), 28.93 (CH2), 29.14 (CH2), 29.45 (CH2), 29.47 (CH2), 30.16 (CH2), 31.60 (CH2), 31.74 (CH2), 
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45.85 (N-CH2), 60.80 (C6), 68.79 (C1), 72.74 (C4), 74.03 (C3), 74.91 (C2), 76.24 (O-CH2), 76.82 (C5). LRMS 
(ESI) m/z: 423.35 [M + Li]+ Calculated for C23H46LiNO5: 423.3536. 
3.30 (1R,2S,3R,4S,5S,6R)-5-(hexylamino)-6-(nonyloxy)cyclohexane-1,2,3,4-tetraol 
 
In a high pressure reaction vessel, concentrated HCl (7 drops) was added to a solution of 3.25 (36mg, 
0.048mmol) in methanol (7mL).  The system was flushed with argon followed by the addition of 10% 
Pd/C (25mg, 0.023mmol). The vessel was then repeatedly filled and evacuated with hydrogen and the 
mixture was hydrogenated at 50 psi for 16 hours with stirring.  The catalyst was removed by vacuum 
filtration through a plug of Celite and was washed with methanol (20mL).  The filtrate was concentrated 
under reduced pressure to provide dark orange crystals. The crystals were dissolved in water (2mL), 
basified with concentrated NH4OH (1mL) to yield a black precipitate and the solution was purified by 
reversed phase chromatography (Thermo Scientific, Hypersep C18, 2000mg, 15mL ) using a gradient of 
water to methanol (0% to 100% MeOH at 20% increments). Fractions containing the product were 
concentrated then lyophilized to yield the HCl salt of 3.30 as a white powder (4mg, 0.009mmol, 20%). 1H 
NMR (500 MHz, CD3OD) δ 0.76-0.88 (m, 6H, CH3), 1.15-1.39 (m, 20H, CH2), 1.47-1.54 (sextet, J = 7Hz, 2H, 
NH-CH2-CH2), 2.52-2.56 (t, J = 10Hz, 1H, H5), 2.79-2.90 (qt, J = 11, 7Hz, 2H, NH-CH2), 3.04-3.29 (m, 5H, 
H1, H2, H3, H4, H6), 3.48-3.52 (dt, J = 7, 2Hz, 1H, O-CH2), 3.92-3.97 (dt, J = 7, 6Hz, 1H, O-CH2).  
13C NMR 
(500 MHz, CD3OD) δ 13.03 (CH3), 24.28 (CH2), 25.86 (CH2), 26.00 (CH2), 26.59 (CH2), 26.74 (CH2), 29.06 
(CH2), 29.30 (CH2), 29.37 (CH2), 30.10 (CH2), 30.14 (CH2), 31.69 (CH2), 46.36 (N-CH2), 61.57 (C5), 72.52 
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(C4), 74.35 (C1), 75.02 (C2), 75.29 (C3), 75.80 (O-CH2), 75.91 (C6). LRMS (ESI) m/z: 390.3 [M - H]
+ 
Calculated for C21H44NO5
+: 390.3214. 
3.31 (1R,2S,3R,4S,5S,6R)-5-(butylamino)-6-(nonyloxy)cyclohexane-1,2,3,4-tetraol 
 
In a high pressure reaction vessel, concentrated HCl (8 drops) was added to a solution of 3.26 (92mg, 
0.13mmol) in methanol (8mL).  The system was flushed with argon followed by the addition of 10% Pd/C 
(68mg, 0.064mmol). The vessel was then repeatedly filled and evacuated with hydrogen and the mixture 
was hydrogenated at 50 psi for 16 hours with stirring.  The catalyst was removed by vacuum filtration 
through a plug of Celite and was washed with methanol (20mL).  The filtrate was concentrated under 
reduced pressure to provide dark orange crystals. The crystals were dissolved in water (2mL), basified 
with concentrated NH4OH (1mL) to yield a black precipitate and the solution was purified by reversed 
phase chromatography (Thermo Scientific, Hypersep C18, 2000mg, 15mL ) using a gradient of water to 
methanol (0% to 100% MeOH at 20% increments). Fractions containing the product were concentrated 
then lyophilized to yield the HCl salt of 3.31 as a pure white powder (34mg,  0.085mmol, 67%). 1H NMR 
(500 MHz, CD3OD) δ  0.83-0.87 (t, J = 7Hz, 3H, CH3), 0.94-0.97 (t, J = 7Hz, 3H, CH3), 1.21-1.35 (m,  12H, 
CH2), 1.37-1.44 (sextet, J = 7Hz, 2H, N-CH2-CH2-CH2), 1.56-1.61 (quintet, J = 7Hz, 2H, O-CH2-CH2), 1.64-
1.70 (quintet, J = 7Hz, 2H, N-CH2-CH2), 2.95-3.00 (t, J = 10 Hz, 1H, H5), 3.03-3.08 (dt, J = 12, 8Hz, 1H, NH-
CH2), 3.12-3.22 (m, 3H, H1, H4, NH-CH2), 3.36-3.45 (m, 3H, H2, H3, H6), 3.56-3.60 (dt, J = 7, 6Hz, 1H, O-
CH2), 4.07-4.12 (dt, J = 7, 6Hz, 1H, O-CH2).   
13C NMR (500 MHz, CD3OD) 12.56 (CH3), 13.06 (CH3), 19.51 
(CH2), 22.34 (CH2), 25.83 (CH2), 27.95 (CH2), 29.05 (CH2), 29.35 (CH2), 29.36 (CH2), 30.03 (CH2), 31.68 
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(CH2), 45.12 (N-CH2), 60.68 (C5), 68.64 (C4), 72.67 (C1), 74.04 (C2), 74.86 (C3), 76.17 (O-CH2), 76.66 (C6). 
LRMS (ESI) m/z: 362.3 [M - H]+ Calculated for C19H40NO5
+: 362.2901 
3.32 (1S,2R,3S,4R,5R,6S)-5-(hexyloxy)-6-(octylamino)cyclohexane-1,2,3,4-tetraol 
 
In a high pressure reaction vessel, concentrated HCl (5 drops) was added to a solution of 3.27 (125mg, 
0.170mmol) in methanol (5mL).  The system was flushed with argon followed by the addition of 10% 
Pd/C (106mg, 1.00mmol). The vessel was then repeatedly filled and evacuated with hydrogen and the 
mixture was hydrogenated at 50 psi for 16 hours with stirring.  The catalyst was removed by vacuum 
filtration through a plug of Celite and was washed with methanol (20mL).  The filtrate was concentrated 
under reduced pressure to provide dark orange crystals. The crystals were dissolved in water (2mL), 
basified with concentrated NH4OH (1mL) to yield a black precipitate and the solution was purified by 
reversed phase chromatography (Thermo Scientific, Hypersep C18, 2000mg, 15mL ) using a gradient of 
water to methanol (0% to 100% MeOH at 20% increments). Fractions containing the product were 
concentrated then lyophilized to yield the HCl salt of 3.29 as a pure white powder (54mg, 0.13mmol, 
77%). 1H NMR (500 MHz, CD3OD) δ 0.84-0.90 (m, 6H, CH3), 1.24-1.40 (m, 16H CH2), 1.56-1.60 (quintet, J 
= 7Hz, 2H, O-CH2-CH2), 1.65-1.70 (quintet, J = 7Hz, 2H, N-CH2-CH2), 2.95-2.99 (t, J = 10Hz, 1H, H6), 3.01-
3.44 (m, 7H, H1, H2, H3, H4, H5, N-CH2), 3.55-3.60 (dt, J = 7, 6Hz, 1H, O-CH2) , 4.08-4.12 (dt, J = 7, 6Hz, 
1H, O-CH2).  
13C NMR (500 MHz, CD3OD) δ 13.14 (CH3), 13.17 (CH3), 22.38 (CH2), 22.43 (CH2), 25.60 (CH2), 
25.62 (CH2), 26.01 (CH2), 26.40 (CH2), 28.93 (CH2), 29.09 (CH2), 29.22 (CH2), 30.16 (CH2), 31.60 (CH2), 
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31.65 (CH2), 31.70 (CH2), 32.30 (CH2), 46.29 (N-CH2), 60.93 (C6), 61.68 (C6), 68.93 (C1), 72.78 (C4), 73.98 
(C3), 74.91 (C2), 76.27 (O-CH2), 76.94 (C6).  LRMS (ESI) m/z: 376.3 [M - H]
+ Calculated for C20H42NO5
+: 
376.3057. 
3.33 (1R,2S,3R,4S,5S,6R)-5-(butylamino)-6-(hexyloxy)cyclohexane-1,2,3,4-tetraol 
 
 
In a high pressure reaction vessel, concentrated HCl (5 drops) was added to a solution of 3.28 (82mg, 
0.12mmol) in methanol (5mL).  The system was flushed with argon followed by the addition of 10% Pd/C 
(76mg, 0.071mmol). The vessel was then repeatedly filled and evacuated with hydrogen and the mixture 
was hydrogenated at 50 psi for 16 hours with stirring.  The catalyst was removed by vacuum filtration 
through a plug of Celite and was washed with methanol (20mL).  The filtrate was concentrated under 
reduced pressure to provide dark orange crystals. The crystals were dissolved in water (2mL), basified 
with concentrated NH4OH (1mL) to yield a black precipitate and the solution was purified by reversed 
phase chromatography (Thermo Scientific, Hypersep C18, 2000mg, 15mL ) using a gradient of water to 
methanol (0% to 100% MeOH at 20% increments). Fractions containing the product were concentrated 
then lyophilized to yield the HCl salt of 3.29 as a pure white powder (33mg, 0.093mmol, 77%). 1H NMR 
(500 MHz, CD3OD) δ 0.84-0.89 (t, J = 7Hz, 3H, CH3), 0.93-0.96 (t, J = 7Hz, 3H, CH3), 1.23-1.34 (m, 6H, CH2), 
1.36-1.43 (sextet, J = 7Hz, 2H, N-CH2-CH2-CH2), 1.55-1.60 (quintet, J = 7Hz, 2H, O-CH2-CH2), 1.64-1.70 
(quintet, J = 7Hz, 2H, N-CH2-CH2), 2.95-2.99 (t, J = 10Hz, 1H, H5), 3.04-3.46 (m, 7H, H1, H2, H3, H4, H6, N-
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CH2), 3.56-3.61 (q, J = 7Hz, O-CH2), 4.06-4.11 (q, J = 7Hz, O-CH2).   
13C NMR (500 MHz, CD3OD) 12.99 (N-
(CH2)3-CH3), 13.27 (O-(CH2)5-CH3), 19.85 (CH2), 22.47 (CH2), 25.67 (CH2), 28.19 (CH2), 30.21 (CH2), 31.72 
(CH2), 46.41 (N-CH2), 61.08 (C5), 69.05 (C4), 72.89 (C1), 74.06 (C2), 74.91 (C3), 76.27 (O-CH2), 77.01 (C6). 
LRMS (ESI) m/z: 320.2 [M - H]+ Calculated for C16H34NO5
+: 320.2431. 
3.34 (1R,2S,3S,4R,5S,6R)-2-azido-3,4,5,6-tetrakis(benzyloxy)cyclohexyl methanesulfonate 
 
A solution of 3.07 (2.00g, 3.70mmol) in pyridine (8mL) was cooled to 0°C in an ice bath. Methanesulfonyl 
chloride (1.43 mL 18.49mmol) was added dropwise and allowed to stir at room temperature overnight 
and under argon. The solution was then concentrated under reduced pressure, co-evaporating with 
toluene.  The residue was dissolved in EtOAc (100mL) and washed with water (100mL), then 1M HCl 
(100ml) and saturated NaHCO3 (100mL). The organics were dried with brine (100mL) and Na2SO4, then 
concentrated under reduced pressure to yield a golden yellow syrup. The thoroughly dry mixture was 
dissolved in DMF (20mL).  NaN3 (241mg, 3.71mmol) was added and allowed to stir at room temperature 
and under argon for 2 days. The reaction was then concentrated under reduced pressure, co-
evaporating with toluene. The residue was dissolved in EtOAc (100mL), washed with water (100mL) 
brine (100mL) and dried over Na2SO4, then concentrated under reduced pressure.   The residue was 
purified by flash chromatography on silica gel (12:1 Hexanes: EtOAc) to yield 3.34 as an orange oil 
(1.01g, 1.57mmol, 42% over both steps).  Spectra was consistent with known data.65 
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3.35 (2S,3R,4R,5S)-2,3,4,5-tetrakis(benzyloxy)-7-azabicyclo[4.1.0]heptanes 
 
A solution of 3.34 (2.00g, 3.107mmol) in diethyl ether (30mL) was cooled to 0°C in an ice bath. LiAlH4 
(270mg, 7.115mmol) was then slowly added and allowed to stir at room temperature overnight under 
argon. EtOAc (20mL) was added to the solution and allowed to stir for 30 minutes to quench the 
reaction.  The organics were washed with water (2 x 50mL), brine (50mL), dried over Na2SO4 and 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
(3:1 hexanes: EtOAc) to yield 3.35 as a white solid (970mg, 1.859mmol, 60%). 1H NMR (500 MHz, CDCl3) 
δ2.32-2.34 (d, J = 6Hz, 1H, H1), 2.48-2.50 (dd, J = 6, 3Hz, 1H, H6), 3.42-3.45 (dd, J = 10, 8Hz, 1H, H2), 
3.61-3.65 (t, J = 8Hz, 1H, H5), 3.83-3.85 (d, J = 8Hz, 1H, H3,)  3.86-3.87, (d, J = 3Hz, 1H, H4), 4.68-4.85 (m, 
8H, CH2-O), 7.23-7.40 (m, 20H, phenyl). 
13C NMR (500 MHz, CD3OD) δ33.23 (C1), 34.37 (C6), 72.84 (CH2-
O), 72.90 (CH2-O), 75.36 (CH2-O), 75.85 (CH2-O), 79.66 (C2), 79.84 (C5), 81.31 (C3), 84.28 (C4), 127.49 
(CH, Phenyl), 127.54 (CH, phenyl), 127.59 (CH, phenyl), 127.64 (CH, phenyl), 127.75 (CH, phenyl), 127.80 
(CH, phenyl), 127.87 (CH, phenyl), 127.87 (CH, Phenyl), 127.91 (CH, Phenyl), 128.04 (CH, Phenyl), 128.13 
(CH, Phenyl), 128.21 (CH, phenyl), 128.31 (CH, phenyl), 128.34 (CH, phenyl), 128.40 (CH, phenyl), 128.50 
(CH, phenyl), 138.17 (C-CH2-O, phenyl),138.84 (C-CH2-O, phenyl), 138.89 (C-CH2-O, phenyl), 138.91 (C-
CH2-O, phenyl).  
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3.36 (2S,3R,4R,5S)-2,3,4,5-tetrakis(benzyloxy)-7-octyl-7-azabicyclo[4.1.0]heptanes 
 
Potassium Carbonate (132mg, 0.959mmol) and 1-iodooctane (0.692ml, 0.383mmol) were added to a 
solution of 3.35 (250mg, 0.479mol) in dry DMF (15mL) and allowed to stir at 50°C overnight under 
argon. The solution was then evaporated to dryness under reduced pressure. The residue was dissolved 
in EtOAc (50mL), washed with water (50mL), brine (50mL), dried over Na2SO4, and concentrated under 
reduced pressure.  The resulting residue was purified by flash chromatography on silica gel (8:1 hexanes: 
EtOAc) to give 3.36 as a yellow oil (180mg, 0.284mmol, 59.3%). 1H NMR (500 MHz, CDCl3) δ 0.84-0.92 (t, 
J = 7Hz, 3H, CH3), 1.27-1.38 (m, 10H, CH2), 1.48-1.56 (quintet, J =  6Hz, 2H, N-CH2-CH2), 1.60-1.62 (d, J = 
6Hz, 1H, H1), 1.82-1.84 (dd, J = 6, 3Hz, 1H, H6), 2.00-2.05 (dt, J = 11, 7Hz, 1H, N-CH2), 2.37-2.42 (dt, J = 
11, 7Hz, 1H, N-CH2), 3.35-3.39 (dd, 10, 8Hz, 1H, H5), 3.57-3.61(dd, 10, 8Hz, 1H, H2), 3.77-3.79 (dd, J = 8, 
3Hz, 1H, H3), 3.80-3.81 (d, J = 8Hz, 1H, H4), 4.69-4.85 (m, 8H, CH2-O), 7.21-7.40 (m, 20H, phenyl).  
13C 
NMR (500 MHz, CDCl3) δ14.20 (CH3), 22.74 (CH2), 27.48 (CH2), 29.35 (CH2), 29.67 (CH2), 29.68 (CH2), 
31.95 (CH2), 41.77 (C1), 42.67 (C6), 61.17 (CH2-N), 72.59 (CH2-O), 72.90 (CH2-O), 75.45 (CH2-O), 75.91 
(CH2-O), 80.08 (C2), 80.50 (C5), 81.31 (C3), 84.46 (C4), 127.44 (CH-C, phenyl), 127.49 (CH-C, phenyl), 
127.58 (CH-C, phenyl), 127.81 (CH-C, phenyl), 127.85 (CH-C, phenyl), 127.96 (CH-C, phenyl), 128.15 (CH-
C, phenyl), 128.37 (CH-C, phenyl), 128.50 (CH-C, phenyl), 138.25 (C-CH2-O, phenyl), 139.00 (C-CH2-O, 
phenyl), 139.04 (C-CH2-O, phenyl), 139.08 (C-CH2-O, phenyl). 
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3.37 (2S,3R,4R,5S)-2,3,4,5-tetrakis(benzyloxy)-7-hexyl-7-azabicyclo[4.1.0]heptane 
 
Potassium Carbonate (132mg, 0.959mmol) and 1-iodohexane (0.565ml, 0.383mmol) were added to a 
solution of 3.35 (250mg, 0.479mol) in dry DMF (15mL) and allowed to stir at 50°C overnight under 
argon. The solution was then evaporated to dryness under reduced pressure. The residue was dissolved 
in EtOAc (50mL), washed with water (50mL), brine (50mL), dried over Na2SO4, and concentrated under 
reduced pressure.  The resulting residue was purified by flash chromatography on silica gel (8:1 hexanes: 
EtOAc) to give 3.37 as a white solid (190mg, 0.314mmol, 65.5%). 1H NMR (500 MHz, CDCl3) δ 0.86-0.93(t, 
J = 7Hz, 3H, CH3), 1.24-1.38 (m, 6H, CH2), 1.49-1.54 (quintet, J =  6Hz, 2H, N-CH2-CH2), 1.61-1.62 (d, J = 
6Hz, 1H, H1), 1.83-1.85 (dd, J = 6, 3Hz, 1H, H6), 2.01-2.06 (dt, J = 11, 7Hz, 1H, N-CH2), 2.37-2.42 (dt, J = 
11, 7Hz, 1H, N-CH2), 3.36-3.40 (dd, 10, 8Hz, 1H, H5), 3.58-3.62 (dd, 10, 8Hz, 1H, H2), 3.77-3.80 (dd, J = 8, 
3Hz, 1H, H3), 3.80-3.82 (d, J = 8Hz, 1H, H4), 4.69-4.85 (m, 8H, CH2-O), 7.23-7.40 (m, 20H, phenyl). 
13C 
NMR (500 MHz, CDCl3) δ14.21 (CH3), 22.72 (CH2), 27.18 (CH2), 29.68 (CH2), 31.95 (CH2), 41.79 (C1), 42.71 
(C6), 61.19 (CH2-N), 72.63 (CH2-O), 72.93 (CH2-O), 75.49 (CH2-O), 75.93 (CH2-O), 80.11 (C2), 80.53 (C5), 
81.35 (C3), 84.50 (C4), 127.48 (CH-C, phenyl), 127.52 (CH-C, phenyl), 127.61 (CH-C, phenyl), 127.84 (CH-
C, phenyl), 127.88 (CH-C, phenyl), 128.00 (CH-C, phenyl), 128.17 (CH-C, phenyl), 128.33 (CH-C, phenyl), 
128.35 (CH-C, phenyl), 128.40 (CH-C, phenyl), 128.53 (CH-C, phenyl), 138.28(C-CH2-O, phenyl), 139.03(C-
CH2-O, phenyl), 139.07(C-CH2-O, phenyl), 139.11(C-CH2-O, phenyl). 
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3.38 (2S,3R,4R,5S)-2,3,4,5-tetrakis(benzyloxy)-7-butyl-7-azabicyclo[4.1.0]heptanes 
 
Potassium carbonate (132mg, 0.959mmol) and 1-iodobutane (0.438ml, 0.383mmol) were added to a 
solution of 3.35 (250mg, 0.479mol) in dry DMF (15mL) and allowed to stir at 50°C overnight under 
argon. The solution was then evaporated to dryness under reduced pressure. The residue was dissolved 
in EtOAc (50mL), washed with water (50mL), brine (50mL), dried over Na2SO4, and concentrated under 
reduced pressure.  The resulting residue was purified by flash chromatography on silica gel (8:1 hexanes: 
EtOAc) to give 3.38 as a yellow oil (151mg, 0.261mmol, 54.5%). 1H NMR (500 MHz, CD3OD) δ 0.87-0.93 
(t, J = 7.2, 3H, CH3), 1.33-1.38 (qd, J = 7, 2.6Hz, 2H, CH2-CH3), 1.46-1.51 (m, 2H, N-CH2-CH2) 1.60-1.61(d, J 
= 6Hz, 1H, H1), 1.82-1.84 (dd, J = 6, 3Hz, 1H, H6) 2.00-2.06 (dt, J = 11, 7Hz, 1H, N-CH2), 2.36-2.41 (dt, J = 
11, 7Hz,  1H, N-CH2), 3.35-3.39 (dd, J = 10, 8Hz, 1H, H5), 3.57-3.61 (dd, J = 10, 8Hz, 1H, H2), 3.76-3.79 
(dd, J = 8, 3Hz, 1H, H3), 3.79-3.81 (d, J = 8Hz, 1H, H4), 4.68-4.84 (m, 8H, O-CH2), 7.22-7.39(m, 20H, 
phenyl). 13C NMR (500 MHz, CD3OD) δ 14.20 (CH3), 20.59 (CH2-CH3), 31.82 (N-CH2-CH2), 41.75 (C1), 42.71 
(C6), 60.81 (CH2-N), 72.63 (CH2-O), 72.92 (CH2-O), 75.47 (CH2-O), 75.93 (CH2-O), 80.12 (C2), 80.52 (C5), 
81.30 (C3), 84.50 (C4), 127.47 (CH-C, phenyl), 127.52 (CH-C, phenyl), 127.61 (CH-C, phenyl), 127.84 (CH-
C, phenyl), 127.87 (CH-C, phenyl), 127.89 (CH-C, phenyl), 128.02 (CH-C, phenyl), 128.17 (CH-C, phenyl), 
128.32 (CH-C, phenyl), 128.34 (CH-C, phenyl), 128.40 (CH-C, phenyl), 128.53 (CH-C, phenyl), 138.27 (C-
CH2-O, phenyl), 139.02 (C-CH2-O, phenyl), 139.07 (C-CH2-O, phenyl), 139.10 (C-CH2-O, phenyl). 
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3.39 (2S,3R,4R,5S)-7-octyl-7-azabicyclo[4.1.0]heptane-2,3,4,5-tetraol 
 
Concentrated NH4OH (75mL) was heated to 60°C to release NH3(g) that passes through a cold water 
condenser and two drying tubes filled with CaSO4 that are cooled in an ice bath. NH3(l) (20mL) was 
condensed by a dry ice condenser into a three neck flask partially submerged in an acetone dry ice slurry 
kept at -78°C.  A small chunk of Na(s) (~100-200mg, 4.35-8.70mmol) was added to the stirring NH3(l) 
producing a persistent deep blue color.  3.36 (253mg, 0.399 mmol) dissolved in THF (3mL) and cooled to 
-78°C in the dry ice bath was added to the stirring solution via cannula and allowed to stir for 4 hours.  
Water (15mL) was added to the solution to quench the reaction and allowed to return to room 
temperature to slowly evaporate NH3(l).  The solution was concentrated under reduced pressure to 
remove NH4OH then redissolved in water (50mL). The organics were extracted with diethyl ether (50mL) 
and the aqueous was concentrated to dryness under reduced pressure. The resulting residue was 
purified by flash chromatography on silica gel (gradient 7:1 CHCl3:MeOH to 100% MeOH) to give 3.39 as 
a white powder (60mg, 0.219 mmol, 55%).  1H NMR (500 MHz, CD3OD) δ 0.91-0.93 (t, J = 7Hz, 3H, CH3), 
1.28-1.40 (m, 10H, CH2), 1.57-1.62 (quintet, J = 7Hz, 2H, N-CH2-CH2), 1.64-1.66 (d, J = 6Hz, 1H, H1), 1.94-
1.96 (t, J = 5Hz, 1H, H6), 2.14-2.19 (dt, J = 11, 7Hz, 1H, N-CH2), 2.38-2.42(dt, J = 11, 7Hz, 1H, N-CH2), 3.05-
3.09 (t, J = 9Hz, 1H, H3), 3.23-3.27(t, J = 9Hz, 1H, H4), 3.64-3.66 (d, J = 8Hz, 1H, H2), 3.70-3.73 (dd, J = 8, 
3Hz, 1H, H5).  13C NMR (500 MHz, CD3OD) δ 13.05 (CH3), 22.34 (CH2), 27.02(CH2), 29.01(CH2), 29.16(CH2), 
29.33(CH2), 31.64(CH2), 44.03 (C1), 44.45 (C6), 60.69 (N-CH2), 71.73 (C3), 72.04 (C4), 72.68 (C5), 76.45 
(C2). LRMS (ESI) m/z: 272.2 [M - H]- Calculated for C14H26NO4
-: 272.1867  
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3.40 (2S,3R,4R,5S)-7-hexyl-7-azabicyclo[4.1.0]heptane-2,3,4,5-tetraol 
 
Concentrated NH4OH (75mL) was heated to 60°C to release NH3(g) that passes through a cold water 
condenser and two drying tubes filled with CaSO4 that are cooled in an ice bath. NH3(l) (20mL) was 
condensed by a dry ice condenser into a three neck flask partially submerged in an acetone dry ice slurry 
kept at -78°C.  A small chunk of Na(s) (~100-200mg, 4.35-8.70mmol) was added to the stirring NH3(l) 
producing a persistent deep blue color.  3.37 (281mg, 0.464 mmol) dissolved in THF (3mL) and cooled to 
-78°C in the dry ice bath was added to the stirring solution via cannula and allowed to stir for 4 hours.  
Water (15mL) was added to the solution to quench the reaction and allowed to return to room 
temperature to slowly evaporate NH3(l).  The solution was concentrated under reduced pressure to 
remove NH4OH then redissolved in water (50mL). The organics were extracted with diethyl ether (50mL) 
and the aqueous was concentrated to dryness under reduced pressure. The resulting residue was 
purified by flash chromatography on silica gel (gradient 7:1 CHCl3:MeOH to 100% MeOH) to give 3.40 as 
a white powder (50mg, 0.204 mmol, 44%).  1H NMR (500 MHz, CD3OD) δ0.91-0.94 (t, J = 7Hz, 3H, CH3), 
1.31-1.41 (m, 6H, CH2), 1.57-1.63 (quintet, J = 7Hz, 2H, N-CH2-CH2), 1.65-1.67 (d, J =  7Hz, 1H, H1), 1.94-
1.96 (t, J = 5Hz, 1H, H6), 2.14-2.20 (dt, J = 11, 7Hz, 1H, N-CH2), 2.37-2.42(dt, J = 11, 7Hz, 1H, N-CH2), 3.06-
3.10 (t, J = 10Hz, 1H, H3), 3.23-3.27(t, J = 10Hz, 1H, H4), 3.64-3.66 (d, J = 8Hz, 1H, H2), 3.71-3.73 (dd, J = 
8, 3Hz, 1H, H5).  13C NMR (500 MHz, CD3OD) δ13.02 (CH3), 22.27 (CH2), 26.70 (CH2), 29.13 (CH2), 31.61 
(CH2), 44.04 (C1), 44.45 (C6), 60.69 (CH2-N), 71.72 (C3), 72.04 (C4), 72.68 (C5), 76.43 (C2). LRMS (ESI) 
m/z: 244.1 [M - H]- Calculated for C12H22NO4
-: 244.1554  
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3.41 (2S,3R,4R,5S)-7-butyl-7-azabicyclo[4.1.0]heptane-2,3,4,5-tetraol 
 
 Concentrated NH4OH (75mL) was heated to 60°C to release NH3(g) that passes through a cold 
water condenser and two drying tubes filled with CaSO4 that are cooled in an ice bath. NH3(l) (20mL) was 
condensed by a dry ice condenser into a three neck flask partially submerged in an acetone dry ice slurry 
kept at -78°C.  A small chunk of Na(s) (~100-200mg, 4.35-8.70mmol) was added to the stirring NH3(l) 
producing a persistent deep blue color.  3.38 (130mg, 0.215mmol) dissolved in THF (3mL) and cooled to 
-78°C in the dry ice bath was added to the stirring solution via cannula and allowed to stir for 4 hours.  
Water (15mL) was added to the solution to quench the reaction and allowed to return to room 
temperature to slowly evaporate NH3(l).  The solution was concentrated under reduced pressure to 
remove NH4OH then redissolved in water (50mL). The organics were extracted with diethyl ether (50mL) 
and the aqueous was concentrated to dryness under reduced pressure. The resulting residue was 
purified by flash chromatography on silica gel (gradient 7:1 CHCl3:MeOH to 100% MeOH) to give 3.41 as 
a white powder (35mg, 0.1611mmol, 75%).  1H NMR (500 MHz, CD3OD) δ0.94-0.97 (t, J = 7 Hz, 3H, CH3), 
1.37-1.44 (q, J = 7 Hz, 2H, CH2-CH3), 1.55-1.61(t, J = 7Hz, 2H, N-CH2-CH2), 1.65-1.66(d, J = 6Hz, 1H, H1), 
1.95-1.96(m, 1H, H6), 2.15-2.20 (dt, J = 10, 7Hz, 1H, N-CH2), 2.37-2.43 (dt, J = 10, 7Hz, 1H, N-CH2), 3.06-
3.09(t, J =  9Hz, 1H, H3), 3.23-3.27(t, J = 9Hz, 1H, H4), 3.64-3.66 (d, J = 8Hz, 1H, H2), 3.70-3.73 (d, J = 8Hz, 
1H, H5). 13C NMR (500 MHz, CD3OD) δ13.04 (CH3), 20.12 (CH2), 31.36 (CH2), 44.05 (C1), 44.43 (C6), 
60.38(CH2-N), 71.73 (C3), 72.04 (C4), 72.67 (C5), 76.44 (C2).  LRMS (ESI) m/z: 216.1 [M - H]- Calculated 
for C10H18NO4
-: 216.1241  
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Chapter 6: Enzymology 
6.1 Production of ABG 
Electro-competent BL21 cells were placed into small vials containing 50µL of LB medium and 50µL of a 
10% glycerol:90% water solution. 1µL of pET-24 ABG-wt vector plasmid solution was added then the 
contents transferred into an electroporator cuvette. The electroporator pulsed at 1200mV for 5.6ms to 
open the cell membranes followed immediately by 100µL of LB medium. The contents of the cuvette 
were transferred into a tube containing 5mL of LB media and allowed to grow at 37°C for 1 hr with 
shaking before 5µL of kanamycin solution (30g/mL) was added. The cells were then plated on a LB media 
containing kanamycin (30µg/mL) and grown overnight at 37° with shaking.  A single colony was selected 
and inoculated in 10mL of LB media and grown at 37° overnight with shaking then frozen at -85°C.  
Frozen cells (1 mL) were selected and grown overnight in a flask containing 25mL of LB medium and 
30µg/mL kanamycin to provide concentrated cell mixture.  The concentrated cell mixture was added to 
450mL of LB medium containing 30µg/mL kanamycin until an OD600nm~ 0.2 was obtained. The cells were 
allowed to grow until an optimal concentration for protein expression of OD600nm~ 0.6 was obtained.  
Isopropyl β-D-1-thiogalactopyranoside (450µL, 0.5M) was added to the flask and the cells were grown 
overnight at room temperature with shaking.  The cells were then isolated by centrifugation (10000 x g) 
and supernatant removed by decanting. Cells were transferred into tubes and resuspended in binding 
buffer ( 30mM HEPES, 500mM NaCl, pH 8.0) with lysozyme (10mg/mL) followed by sonication (3s pulse, 
6s delay, 3min x 3 with 3 min cooling between).  The mixture was then centrifuged (10000 x g) to isolate 
solid cellular components and the supernatant containing ABG. The ABG in the supernatant was purified 
by loading onto a  nickel affinity column, washed (30mM imidazole, 500mM NaCl, pH 7.4), and then 
eluted (300mM imidazole, 500mM NaCl, pH 7.4).  The fractions containing ABG were detected from 
hydrolysis of the dilute substrate 2,4-DNP-β-D-Glc by observing the yellow 2,4-dinitrophenolate product.  
The fractions were concentrated using a 10KDa molecular weight cut-off centrifuge tube.  The 
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concentrated solution was then transferred into small vials and concentration determined by UV Vis 
spectroscopy using the extinction coefficient (E280nM = 2.20cm
2mg-1) as a 3.58mg/mL solution. 
6.2 ABG and GCase Competitive Kinetics 
 The human β-glucocerebroside analogue imiglucerase was obtained from used patient vials of 
Cerezyme® that were donated after use. Full vials contained a solution of 424 units of imiglucerase, 
340mg mannitol, 104mg trisodium citrate, 36mg disodium hydrogen citrate, and 1.06mg polysorbate 80 
in 10mL water.  The buffer used in all kinetics involving GCase was 50mM acetate, 0.2% v/v trition X-100, 
0.3% w/v sodium taurocholate and pH 5.5. Agrobacterium sp. β-Glucosidase was produced by 
transforming Escherichia coli cells with the ABG plasmid and inducing production of the enzyme as 
described above.  The buffer used in all kinetics involving ABG was 50mM phosphate and pH 6.8. The 
running buffer used in the cell lysate assays were 0.1% BSA, 0.15% v/v triton x-100, 0.1M phosphate, 
and either 0.125% sodium taurocholate and pH 5.9, or 1.2% sodium taurocholate and pH 5.5.  The stop 
buffer used in the lysate assays was 0.1M NaOH and 0.1M glycine.  
 The continuous assays were all performed on the Biotek Synergy 4 hybrid multi-mode reader 
using 2,4-dinitrophenyl-β-D-glucopyranoside (3.04) as the substrate.  Determined by Bradford assay, the 
concentration of GCase used for the competitive inhibitors was 4.14nM and for the aziridine inactivators 
was 41.4nM.  Calculated from the ABG extinction coefficient of 2.20cm2/mg, the concentration used for 
the competitive inhibitors was 5nM and for the aziridine inactivators was 50nM.  The reactions were 
measured by the release of 2,4-dinitrophenolate at 400nM.  The initial rates of the reactions were 
determined from the resulting slope of the absorbance vs. time graphs.  For the competitive inhibitors 
the initial rates were fit to the non-linear regression model of Equation 2.1 using GraphPad Prism to 
calculate Ki values.  
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Equation 2.1:       
       
     
   
  
     
 
The aziridine inactivators had their initial rates fit to the one phase decay equation using the 
GraphPad Prism software utilizing equation 2.3 to give Kobs which was then fit to Equation 2.4 with ABG 
and Equation 2.5 with GCase. 
Equation 2.3:          –          
               
Equation 2.4          
     
      
 
Equation 2.5          
     
  
 
 The stopped assays of the cell lyates were all performed on the Biotek Synergy 4 hybrid multi-
mode reader and used the substrate 4-methylumbelliferyl β-D-glucopyranoside.  HeLa cells were seeded 
into wells and grown up to 80% confluency in media containing DMEM with 10% serum. The aziridine 
inhibitors were then incubated with the cells in concentrations of 10nM, 100nM and 1mM overnight. 
The cells were then washed and lysed.  The cell lysate was centrifuged and the supernatant was isolated 
and frozen at -80°C.  A Bradford assay was performed on the lysates to determine the concentration of 
protein.  In triplicate, 10µL of the Lysates in 190µL of buffer were incubated at 37°C before initiation by 
addition of 4-MuGlc with stirring. After 10 minutes, 50µL of the reaction mixture was removed and 
added to 200µL of the stop buffer. Then 200µL of the stopped solution was measured for the 
fluorescence of 4-methylumbelliferone which was excited at 365nm to emit at 448nm.  The background 
emission from spontaneous hydrolysis of 4-MuGlc was removed and the emissions were represented as 
a relative value to the cell lysate blanks which were not incubated in the presence of any inhibitors.  
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Chapter 7: NMR Spectra 
1H NMR Spectrum (500 MHz, CD2OD) of 3.04 
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1H NMR Spectrum (500 MHz, D2O) of 3.05 
 
13C NMR Spectrum (500 MHz, D2O) of 3.05 
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1H NMR Spectrum (500 MHz, CD3OD) of 3.07 
 
13C NMR Spectrum (500 MHz, CD3OD) of 3.07 
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1H NMR Spectrum (500 MHz, CDCl3) of 3.11 
 
13C NMR Spectrum (500 MHz, CDCl3) of 3.11 
 
112 
 
1H NMR Spectrum (500 MHz, CDCl3) of 3.12 
 
13C NMR Spectrum (500 MHz, CDCl3) of 3.12 
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1H NMR Spectrum (500 MHz, CDCl3) of 3.13 
 
13C NMR Spectrum (500 MHz, CDCl3) of 3.13
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1H NMR Spectrum (500 MHz, CDCl3) of 3.14 
 
13C NMR Spectrum (500 MHz, CDCl3) of 3.14 
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1H NMR Spectrum (500 MHz, CDCl3) of 3.16 
 
13C NMR Spectrum (500 MHz, CDCl3) of 3.16 
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1H NMR Spectrum (500 MHz, CDCl3) of 3.17 
 
13C NMR Spectrum (500 MHz, CDCl3) of 3.17
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1H NMR Spectrum (500 MHz, CD3OD) of 3.19 
 
13C NMR Spectrum (500 MHz, CD3OD) of 3.19 
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1H NMR Spectrum (500 MHz, CD3OD) of 3.20 
 
13C NMR Spectrum (500 MHz, CD3OD) of 3.20 
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1H NMR Spectrum (500 MHz, CD3OD) of 3.21 
 
13C NMR Spectrum (500 MHz, CD3OD) of 3.21 
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1H NMR Spectrum (500 MHz, CDCl3) of 3.22 
 
13C NMR Spectrum (500 MHz, CDCl3) of 3.22 
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1H NMR Spectrum (500 MHz, CDCl3) of 3.23 
 
13C NMR Spectrum (500 MHz, CDCl3) of 3.23 
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1H NMR Spectrum (500 MHz, CDCl3) of 3.24 
 
13C NMR Spectrum (500 MHz, CDCl3) of 3.24 
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1H NMR Spectrum (500 MHz, CDCl3) of 3.25 
 
13C NMR Spectrum (500 MHz, CDCl3) of 3.25 
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1H NMR Spectrum (500 MHz, CDCl3) of 3.26 
 
13C NMR Spectrum (500 MHz, CDCl3) of 3.26 
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1H NMR Spectrum (500 MHz, CDCl3) of 3.27 
 
13C NMR Spectrum (500 MHz, CDCl3) of 3.27 
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1H NMR Spectrum (500 MHz, CDCl3) of 3.28 
 
13C NMR Spectrum (500 MHz, CDCl3) of 3.28 
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1H NMR Spectrum (500 MHz, CD3OD) of 3.29 
 
13C NMR Spectrum (500 MHz, CD3OD) of 3.29 
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1H NMR Spectrum (500 MHz, CD3OD) of 3.30 
 
13C NMR Spectrum (500 MHz, CD3OD) of 3.30 
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1H NMR Spectrum (500 MHz, CD3OD) of 3.31 
 
13C NMR Spectrum (500 MHz, CD3OD) of 3.31 
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1H NMR Spectrum (500 MHz, CD3OD) of 3.32 
 
13C NMR Spectrum (500 MHz, CD3OD) of 3.32 
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1H NMR Spectrum (500 MHz, CD3OD) of 3.33 
 
13C NMR Spectrum (500 MHz, CD3OD) of 3.33 
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1H NMR Spectrum (500 MHz, D2O) of 3.35 
 
13C NMR Spectrum (500 MHz, D2O) of 3.35 
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1H NMR Spectrum (500 MHz, CDCl3) of 3.36 
 
13C NMR Spectrum (500 MHz, CDCl3) of 3.36 
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1H NMR Spectrum (500 MHz, CDCl3) of 3.37 
 
13C NMR Spectrum (500 MHz, CDCl3) of 3.37 
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1H NMR Spectrum (500 MHz, CDCl3) of 3.38 
 
13C NMR Spectrum (500 MHz, CDCl3) of 3.38 
 
136 
 
1H NMR Spectrum (500 MHz, CD3OD) of 3.39 
 
13C NMR Spectrum (500 MHz, CD3OD) of 3.39 
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1H NMR Spectrum (500 MHz, CD3OD) of 3.40 
 
13C NMR Spectrum (500 MHz, CD3OD) of 3.40 
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1H NMR Spectrum (500 MHz, CD3OD) of 3.41 
 
13C NMR Spectrum (500 MHz, CD3OD) of 3.41 
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Chapter 8: Appendix 
8.1 Equations for Fundamental Enzyme Kinetics 
8.1.1 Michaelis-Menten Kinetics 
The current form of enzyme kinetics was proposed by Leonor Michaelis and Maud Leonora Menten in 
1913 and refined by George Briggs and John Burdon Sanderson Haldane in 1925.79 The final Michaelis-
Menton (M-M) equation relies on a number of assumptions to allow for its derivation and they are as 
follows:  
A1) In the initial stages of the reaction [P]  0. 
A2) Throughout the reaction, ES is in a steady state therefore [ES] is constant 
A3) The enzyme only exists as [E] and [ES] with no [EP].  
A4) The catalytic step (formation of E + P) is slower than the binding step (ES formation) and dissociation 
step (ES into E + S) 
A5) [S] >> [E]0 so that S forming ES is negligible and [S] remains constant throughout the reaction 
Free enzyme (E) combines with free substrate (S) to form an enzyme-substrate complex (ES) that reacts 
to produce free enzyme and free product (P).  All steps are in equilibrium with rate constants k1 and k-1 
for the formation of ES and k2 and k-2 for the formation of product shown in the scheme below.  
 
If we use the first assumption (A1) that [P] is very small like in the initial stages of the reaction where 
velocity is measured then the reverse rate k-2 is minimal thus the scheme becomes:  
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Under the assumption of steady state conditions (A2) where [ES] remains constant we have: 
     
  
                               (1) 
Following assumption (A3), the total concentration of enzyme present in the reaction [E]0 is the sum of 
[E] and [ES]: 
                 (2) 
Substituting (2) into (1) and solving for [ES] we get: 
     
         
     
       
  
 
  (3) 
If we assume the catalysis is rate limiting (A4) so that k2< k1 and k-1 then: 
            (4) 
We can then express V0 with measurable values by substituting (3) into (4): 
          
           
     
       
  
 
  (5) 
The rate constants (k-1 +k2)/k1 can be grouped into a single term Km known as the Michaelis constant.  
Additionally, if [S] >> Km then enzyme bound with substrate approaches total enzyme or [E]0  ES, which 
corresponds with the maximal velocity (Vmax)using equation (4). Substituting these into (5) we derive the 
Michaelis-Menten equation: 
   
       
      
  (6) 
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When [S] = Km, then: 
   
       
    
 
    
 
  
 Therefore we can determine Vmax and Km from a single M-M plot of velocity versus time. An example 
of the M-M plot is shown in Figure A1 below. 
 
Figure A1: A general plot displaying M-M enzyme kinetics 
 
8.1.2 Enzyme Kinetics with a Reversible Inhibitor 
Michaelis-menten kinetics can be applied to the enzyme kinetics in the presence of a competitive 
inhibitor.  The same assumptions apply but with the additions of:  
A3*) The enzyme only exists as [E], [ES], and [EI]* with no [EP].  
A6) Throughout the reaction EI is in a steady state therefore [EI] is constant 
A7) [I] >> [E]0 so that I forming EI is negligible and [I] remains constant throughout the reaction 
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Like with regular M-M kinetics, free enzyme (E) combines with free substrate (S) to form an enzyme-
substrate complex (ES) that reacts to produce free enzyme and free product (P), but there is also free 
enzyme that combines with inhibitor (I) to form an enzyme-inhibitor complex (EI).  All steps are in 
equilibrium with rate constants k1 and k-1 for the formation of ES and k2 and k-2 for the formation of 
product and K3 and K-3 for the formation of EI shown in the scheme below.  
 
If we follow assumptions A2 and A6 where ES and EI are in steady state then: 
 
     
  
                              (1) 
     
  
                     (7) 
Rearranging (1) to define [E] gives: 
  
    
            
     
 
      
   
  (8) 
Substituting (8) into (7) and rearranging to define [EI] and simplifying k3/k-3 = Ki gives: 
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  (9) 
Following assumption A3* total enzyme concentration is: 
[E]0 = [E] + [ES] + [EI]  (10) 
Substituting (9) and (8) into into (10): 
   
      
   
       
         
     
      
  
   
    
     
     
   (11) 
Solving for [ES] gives: 
     
       
            
   
  
  
  (12) 
Substituting (12) into (4) gives us the velocity: 
 
          
         
            
   
  
  
  (12) 
When [S] >> Km then enzyme bound with substrate approaches total enzyme or [E]0  ES, which 
corresponds with the maximal velocity (Vmax) Therefore Vmax = k2[E]0 and the equation enters its M-M 
form:  
          
       
            
   
  
  
  (13) 
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8.1.3 Enzyme Kinetics with a Mechanism-Based Inactivator 
The kinetics of a mechanism-based inhibitor resembles M-M kinetics, retaining the many of the same 
assumptions.  However, instead of the assumptions made with substrate it is with inhibitor. The scheme 
of an irreversible mechanism-based inhibitor is shown in the scheme below: 
 
Where EI is intact inhibitor bound to the enzyme active site but free to dissociate and E-I is enzyme 
covalently inactivated by the inhibitor.  If we replace [S] with [I] and define ki = k2 and Ki = (k-1/k1) then 
equation (5) becomes: 
   
          
        
    
   
 
  (14) 
Where we see pseudo first-order kinetics with respect to [E].  
If we assume k-1 >> k2 or the rate of dissociation is much faster than the rate of inactivation then: 
   
          
      
          (15) 
Where: 
      
       
      
  (16) 
If Ki >> [I] which is the case when the inhibitor rapidly inactivates the enzyme at low concentrations then 
the equation becomes: 
      
       
  
  (17) 
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Kobs is the observed rate constant for the loss of enzyme activity which can be obtained from fitting the 
enzyme activity to an exponential decay equation.  
